



A. Dimitrios Colevas, MD

Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)

Medicine - Oncology

 Curriculum Vitae available Online

CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

875 Blake Wilbur Dr Rm 2328

MC 5826

Stanford, CA 94305

Tel (650) 724-9707 **Fax** (650) 498-5800

Bio

CLINICAL FOCUS

- Cancer > Head and Neck Cancer
- Oncology (Cancer)
- developmental therapeutics
- investigational new drugs
- Adverse event(toxicity) evaluation and reporting
- Thyroid Cancer
- combined chemotherapy and radiation treatment
- Medical Oncology

ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Medicine - Oncology
- Professor - University Medical Line (By courtesy), Otolaryngology (Head and Neck Surgery)
- Professor - University Medical Line (By courtesy), Radiation Oncology - Radiation Therapy
- Member, Stanford Cancer Institute

PROFESSIONAL EDUCATION

- Residency: Johns Hopkins University School of Medicine (1992) MD
- Internship: Johns Hopkins University School of Medicine (1990) MD
- Medical Education: Johns Hopkins University School of Medicine (1989) MD
- Board Certification: Medical Oncology, American Board of Internal Medicine (1995)
- Fellowship: Dana Farber Cancer Institute Hematology Oncology Fellowship (1995) MA
- B. A., Columbia , Chemistry (1985)

- M.D., Johns Hopkins , Medicine (1989)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Multi- modality treatment of Head and Neck Cancer

Phase 1 clinical trials

CLINICAL TRIALS

- Gemcitabine + Docetaxel + Toripalimab(GDT) Induction in EBV Associated Nasopharyngeal Carcinoma(NPC), Recruiting
- Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer, Recruiting
- Phase 2 Study of Nivolumab and Ipilimumab with or without cabozantinib in patients with advanced NPC, Recruiting
- Phase 3 of petosemtamab in incurable, metastatic/recurrent head and neck squamous cell carcinoma, Recruiting
- Phase Ib/II Nanatinostat &Valganciclovir in EBV+ ST & +/-Pembrolizumab in Nasopharyngeal Carcinoma, Recruiting
- Phase II Nivolumab +/-BMS-986016(Relatlimab) in Recurrent/Metastatic Nasopharyngeal Carcinoma, Recruiting
- Phase III Pembrolizumab +/- Petosemtamab in First-LineTreatment of Recurrent/Metastatic PD-L1+ HNSCC, Recruiting
- Phase TBD Multicenter Cancer Biospecimen Collection Study, Recruiting
- SRF114-101: A Phase 1 Study Of CHS-114 In Participant With Advanced Solid Tumors, Recruiting
- BIBW 2992 (Afatinib) in Head & Neck Cancer, Not Recruiting
- Biopsy of Human Tumors for Cancer Stem Cell Characterization: A Feasibility Study, Not Recruiting
- Expanded Access Cabozantinib in Unresectable Locally Advanced/ Metastatic Medullary Thyroid Cancer, Not Recruiting
- FNA Tumor Sampling for CD137 Modulation: A Pilot Study, Not Recruiting
- Imaging and Biomarkers of Hypoxia in Solid Tumors, Not Recruiting
- Oral Arsenic Trioxide and Itraconazole in Advanced Basal Cell Carcinoma, Not Recruiting
- Ph 1 Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Cancer During Surgical Procedures, Not Recruiting
- Ph 1 Panitumumab-IRDye800 Optical Imaging Agent to Detect Head and Neck Cancer During Surgery, Not Recruiting
- Phase 0 Pilot off label use of Arsenic Trioxide for Basal Cell Carcinoma (BCC), Not Recruiting
- Phase 1/2 Ad/PNP-F-araAMP+Co-Admin of Fludarabine Phosphate in Recurrent Local Head &Neck Cancer , Not Recruiting
- Phase 1b Nivolumab in Autoimmune Disorders and Advanced Malignancies (AIM-NIVO), Not Recruiting
- Phase 1b Urelumab + Cetuximab in Advanced / Metastatic CRC or SCCHN, Not Recruiting
- Phase 1B/2 Tabelecleucel +/- Pembrolizumab in Recurrent Metastatic EBV in Nasopharyngeal Carcinoma, Not Recruiting
- Phase I 1st-In-Human REGN2810 Programmed Death-1 Tx +/-Other Anti-Cancer Tx in Advanced Malignancies, Not Recruiting
- Phase I ABBV-368 (Single Agent & Combination in Locally Advanced or Metastatic Solid Tumors, Not Recruiting
- Phase I Atezolizumab (MPDL3280A) IV - Single Agent in Locally Advanced or Metastatic Solid Tumors, Not Recruiting
- Phase I CUDC-101 with Concurrent Cisplatin and XRT in Locally Advanced HPV- Head & Neck Cancer, Not Recruiting
- Phase I CUE-101+/-Pembrolizumab in HPV16+ Recurrent/Metastatic Head&Neck SquamousCellCarcinoma(HNSCC, Not Recruiting
- Phase I LY2940680 in Advanced Cancer or Advanced Basal Cell Carcinoma, Not Recruiting

- Phase I Safety Testing Nivolumab +Chemotherapy in Intermediate &High-Risk Advanced Head &Neck Cancer, Not Recruiting
- Phase I to Evaluate Immunological Response to PD-(L)1 Inhibition in SquamousCellCarcinoma of the H&N, Not Recruiting
- Phase I/Ib Ciforadenant Single Agent & Combo w/ Atezolizumab in Selected Incurable Cancers, Not Recruiting
- Phase I/II Anti-CD27 Antibody(Varlilumab) + Anti-PD-1(Nivolumab) in Advanced Refractory Solid Tumors, Not Recruiting
- Phase I/IIa NovelSmallMolecule EBNA1 Inhibitor VK2019 in EBVirus+ NasopharyngealCancer & EBV-Cancers, Not Recruiting
- Phase Ib GDC-0449 + Rosigilitazone or Oral Contraceptive in Locally Advanced/Metastatic Solid Tumors, Not Recruiting
- Phase Ib Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma, Not Recruiting
- Phase Ib Topically-Applied AG013 in Induction Chemo for Head and Neck Cancers, Not Recruiting
- Phase Ib/II IPH2201 & Cetuximab in HPV (+) & HPV (-) Recurrent or Metastatic SCC of the Head & Neck, Not Recruiting
- Phase II Capecitabine in Advanced or Recurrent Squamous Cell Carcinoma of the Skin, Not Recruiting
- Phase II Cemiplimab alone and in Combo w/ RP1 in Advanced Cutaneous Squamous Cell Carcinoma, Not Recruiting
- Phase II Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients with SCCHN, Not Recruiting
- Phase II EBNA1 Inhibitor VK 2019 in EBV Positive Nasopharyngeal Cancer &Other EBV AssociatedCancers, Not Recruiting
- Phase II GSK1363089 for Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck, Not Recruiting
- Phase II in p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer, Not Recruiting
- Phase II INCAGN01876 in Combination with Immunotherapy in Recurrent or Metastatic HNSCC, Not Recruiting
- Phase II Induction Chemo then Cetuximab + Low/Standard Dose IMRT in HPV Resectable SCC of Oropharynx, Not Recruiting
- Phase II Ipatasertib +/- Pembrolizumab in 1st Line Tx of Recurrent / Metastatic SCC of the Head&Neck, Not Recruiting
- Phase II IV GC4419 in Cisplatin + IMRT in Non-Metastatic Squamous Cell Carcinoma, Not Recruiting
- Phase II Magrolimab Combination Therapy in Head and Neck Squamous Cell Carcinoma, Not Recruiting
- Phase II MEHD7945A vs Cetuximab in Recurrent / Metastatic HNSCC for Progression after Platinum Chemo, Not Recruiting
- Phase II Neoadjuvant &Adjuvant Tx IRX-2 Regimen in Newly Dx Stage II / III / IVA SCC of Oral Cavity, Not Recruiting
- Phase II of TH-4000 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin, Not Recruiting
- Phase II Pembrolizumab +/- BNT113 in HNSCC Which is HPV16+ and Expresses PD-L1, Not Recruiting
- Phase II Pembrolizumab in Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC), Not Recruiting
- Phase II PR-104 in Treatment Naïve and Sensitive-relapse Small Cell Lung Cancer, Not Recruiting
- Phase II REGN2810 in Advanced Basal Cell Carcinoma, Not Recruiting
- Phase II REGN2810-Fully Human Monoclonal Anitbody to PD-1 in Advncd Cutaneous Squamous CellCarcinoma, Not Recruiting
- Phase II Rigosertib in Relapsed, Metastatic, Platinum-resistant, HPV + or - Squamous Cell Carcinoma, Not Recruiting
- Phase II Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma, Not Recruiting
- Phase II Surgery + Low/Std Dose IMRT in Resectable p16+ Locally Advanced Oropharynx CA, Not Recruiting
- Phase II/III Adjuvant RT w/Cisplatin Docetaxel-Cetuximab or Cisplatin-Atezolizumab in HighRisk HNSCC, Not Recruiting
- Phase II/III Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus Deoxyribonucleic Acid , Not Recruiting
- Phase III Cabozantinib (XL184) in Radioiodine-Refractory Differentiated Thyroid Cancer , Not Recruiting
- Phase III Gemcitabine & Carboplatin +/- Autologous EBV Cytotoxic T Cells in Nasopharyngeal Carcinoma, Not Recruiting
- Phase III Immunotherapy +/- Consolidative RT in Oligometastatic Head & Neck Squamous Cell Carcinoma, Not Recruiting
- Phase III Nivolumab in Combo w/Ipilimumab vs Cetuximab +Cisplatin/Carboplatin +Fluorouracil in SCCHN, Not Recruiting
- Phase III Nivolumab vs Investigator's Choice in Recurrent/Metastatic Platinum-refractory SCCHN, Not Recruiting
- Phase III of MEDI4736 Monotherapy or MEDI4736 + Tremelimumab vs SoC in SCCHN, Not Recruiting

- Phase III Pembrolizumab vs Placebo as in HighRisk Locally Advanced Cutaneous Squamous Cell Carcinoma, Not Recruiting
- Phase III Platinum-Gemcitabine +/-Nivolumab in 1st-Line Recurrent/Metastatic NasopharyngealCarcinoma, Not Recruiting
- Phase III Radiotherapy + Cetuximab vs Chemotherapy in HPV-associated Oropharynx Cancer, Not Recruiting
- Phase III Sorafenib vs Placebo in Local Advanced/Metastatic RAI-Refractory Differentiated Thyroid CA, Not Recruiting
- Phase III XL184 vs Placebo for Unresectable, Locally Advanced or Metastatic Medullary Thyroid Cancer, Not Recruiting
- Pilot Dabrafenib and Trametinib in BRAF Mutated Ameloblastoma, Not Recruiting
- Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors, Not Recruiting
- Pilot Sonidegib & BKM120 For the Treatment of Advanced Basal Cell Carcinomas, Not Recruiting
- Expanded Access Lenvatinib for Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer, Not Specified
- Phase II 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC, Not Specified
- Phase II Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer, Not Specified
- Phase II Ozuriftamab Vedotin (BA3021) in PD-1/L1 Failure Patients w/ Recurrent or Metastatic SCCHN, Not Specified

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Medicine (Masters Program)

Publications

PUBLICATIONS

- **Update on Imaging of Nasopharyngeal Carcinoma.** *Radiologic clinics of North America*
Fischbein, N. J., Colevas, A. D., Le, Q. T., Pham, N.
2026; 64 (1): 17-34
- **Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experience.** *Journal of the National Cancer Institute*
Sousa, L. G., Edward Bates, J., Anand, P., Caudell, J. J., Colevas, A. D., Runge, C. L., Sharon, J. D., Awan, M., Beadle, B. M., Choe, J. H., Gidley, P. W., Harari, P. M., Henson, et al
2025
- **Cisplatin, immunotherapy, and chemoradiation in nasopharyngeal carcinoma: How far should one trial move the needle?** *Med (New York, N.Y.)*
Sun, F., Colevas, A. D.
2025; 6 (11): 100917
- **Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas.** *The Lancet. Oncology*
Tang, L. L., Huang, C. L., Lin, S. J., Le, Q. T., O'Sullivan, B., Yom, S. S., Huang, S. H., Chan, A. W., Lee, N., Pan, J. J., Mejia, M. B., Ahn, Y. C., Wong, et al
2025; 26 (9): e477-e487
- **A safety, feasibility, and efficacy study of gemcitabine plus docetaxel plus toripalimab (GDT) induction as part of a curative sequential chemoradiation for patients with locoregional EBV-associated nasopharyngeal carcinoma (NPC)**
Colevas, A. D., Khan, S., Pinto, H., Biedermann, S., Lai, S., Winters, E., Beadle, B.
ELSEVIER.2025
- **Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas** *LANCET ONCOLOGY*
Tang, L., Huang, C., Lin, S., Le, Q., O'Sullivan, B., Yom, S. S., Huang, S., Chan, A. W., Lee, N., Pan, J., Mejia, M. A., Ahn, Y., Wong, et al
2025; 26 (9): e488-e498
- **Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas** *LANCET ONCOLOGY*

- Tang, L., Huang, C., Lin, S., Le, Q., O'Sullivan, B., Yom, S. S., Huang, S., Chan, A. W., Lee, N., Pan, J., Mejia, M. A., Ahn, Y., Wong, et al
2025; 26 (9): e477-e487
- **Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas.** *The Lancet. Oncology*
Tang, L. L., Huang, C. L., Lin, S. J., Le, Q. T., O'Sullivan, B., Yom, S. S., Huang, S. H., Chan, A. W., Lee, N., Pan, J. J., Mejia, M. B., Ahn, Y. C., Wong, et al
2025; 26 (9): e488-e498
 - **Can Chemotherapy Emerge From the Shadows in Resectable Cutaneous Squamous Cell Carcinoma?** *JAMA otolaryngology-- head & neck surgery*
Divi, V., Colevas, A. D.
2025
 - **Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy.** *JACC. CardioOncology*
Cheng, E., Ivanovic, M., Chan, A., Xu, S., Franquiz, M., Lee, C., You, J., Fazal, M., Le Guen, Y., Batchelder, R., Reddy, S. A., Katsumoto, T., Ramchandran, et al
2025
 - **Update: Immunotherapeutic Strategies in HPV-Associated Head and Neck Squamous Cell Carcinoma.** *Viruses*
Sun, F., Colevas, A. D.
2025; 17 (5)
 - **Cost of Neoadjuvant Immunotherapy vs Up-Front Surgery in Cutaneous Squamous Cell Carcinoma: A Post Hoc Analysis of a Nonrandomized Clinical Trial.** *JAMA otolaryngology-- head & neck surgery*
Wu, S. S., Colevas, A. D., Martinez Ramirez, L., Megwalu, U. C., Chen, M. M., Atwell, A., Divi, V.
2025
 - **NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2025.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Colevas, A. D., Cmclak, A. J., Pfister, D. G., Spencer, S., Adkins, D., Birkeland, A. C., Brizel, D. M., Busse, P. M., Caudell, J. J., Durm, G., Fakhry, C., Galloway, T., Geiger, et al
2025; 23 (2): 2-11
 - **First-in-Human clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein-Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic studies.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Colevas, A. D., Talebi, Z., Winters, E., Even, C., Lee, V. H., Gillison, M. L., Khan, S. A., Lu, R., Pinsky, B. A., Soldan, S. S., Vladmirova, O., Lieberman, P. M., Messick, et al
2025
 - **Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study.** *Journal for immunotherapy of cancer*
Flanagan, K. C., Earls, J., Hiken, J., Wellinghoff, R. L., Ponder, M. M., McLeod, H. L., Westra, W. H., Vavinskaya, V., Sutton, L., Deichaite, I., Macdonald, O. K., Welaya, K., Wade, et al
2024; 12 (11)
 - **Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging Classification.** *JAMA oncology*
Pan, J. J., Mai, H. Q., Ng, W. T., Hu, C. S., Li, J. G., Chen, X. Z., Chow, J. C., Wong, E., Lee, V., Ma, L. Y., Guo, Q. J., Liu, Q., Liu, et al
2024
 - **A Survival Analysis of Patients with Radiation -Induced Cancers after Prior Radiation for Head and Neck Cancer**
Laseinde, E., Guan, L., Hildebrand, R., Meurice, N., Gensheimer, M. F., Beadle, B. M., Holsinger, F. C., Sunwoo, J., Baik, F. M., Sirjani, D., Divi, V., Kaplan, M. J., Pinto, et al
ELSEVIER SCIENCE INC.2024: E764
 - **Automated patient selection and care coaches to increase advance care planning for cancer patients.** *Journal of the National Cancer Institute*
Gensheimer, M. F., Teuteberg, W., Patel, M. I., Gupta, D., Noroozi, M., Ling, X., Fardeen, T., Seevaratnam, B., Lu, Y., Alves, N., Rogers, B., Asuncion, M. K., Denofrio, et al
2024
 - **Gemcitabine, carboplatin, and Epstein Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized Phase 3 trial.** *Annals of oncology : official journal of the European Society for Medical Oncology*

- Toh, H. C., Yang, M. H., Wang, H. M., Hsieh, C. Y., Chitapanarux, I., Ho, K. F., Hong, R. L., Ang, M. K., Colevas, A. D., Sirachainan, E., Lertbutsayanukul, C., Ho, G. F., Nadler, et al
2024
- **Exploratory efficacy and translational results from the safety run in of AHEAD-MERIT, a phase II trial of first line pembrolizumab plus the fixed-antigen cancer vaccine BNT113 in advanced HPV16+HNSCC**
Saba, N. F., Klinghammer, K., Castelluci, E., Colevas, A. D., Rutkowski, T., Thurner, D., Mueller-Richter, U., Maio, M., Grewal, J. S., Ottensmeier, C. H., Dias, J., Yang, H., Das, et al
ELSEVIER.2024: S627
 - **Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). *Oral oncology***
Sun, L., Cohen, R. B., Dimitrios Colevas, A.
2024; 158: 106997
 - **Nasopharyngeal cancer mortality in disaggregated Asian and non-Asian Americans. *Head & neck***
Hung, G. A., Vohra, S., Kim, G., Jamal, A., Srinivasan, M., Huang, R. J., Kim, G., Palaniappan, L., Colevas, A. D.
2024
 - **Nasopharyngeal cancer mortality in disaggregated Asian and non-Asian Americans**
Hung, G. A., Vohra, S., Kim, G., Jamal, A., Srinivasan, M., Huang, R. J., Kim, G., Palaniappan, L., Colevas, A.
LIPPINCOTT WILLIAMS & WILKINS.2024
 - **A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck**
Thomas, J., Bruce, J., Li, Z., Lorch, J. H., Phillips, T., Villaflor, V., Ruel, C., Palmer, J., Gutkind, J., Villalona-Calero, M., Colevas, A.
LIPPINCOTT WILLIAMS & WILKINS.2024
 - **Safety of tabellecleucel with pembrolizumab in recurrent/metastatic Epstein-Barr virus-associated nasopharyngeal carcinoma**
Colevas, A., Cohen, R. B., Park, J., Pfister, D. G., Massarelli, E., Li, Z., Xing, B., Dinavahi, R., Mehta, A.
LIPPINCOTT WILLIAMS & WILKINS.2024
 - **A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+head and neck squamous cell cancer (R/M HNSCC).**
Colevas, A., Chung, C. H., Adkins, D., Rodriguez, C. P., Park, J., Gibson, M. K., Sukari, A., Worden, F. P., Johnson, F. M., Saba, N. F., Burtness, B., Julian, R., Bauman, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
 - **Platinum/taxane/pembrolizumab vs Platinum/5-fluorouracil/pembrolizumab in recurrent/metastatic Head and Neck Squamous Cell Carcinoma (r/m HNSCC)**
Sun, L., Cohen, R., Colevas, A. D.
ELSEVIER SCIENCE INC.2024: E34-E35
 - **Safety and Tolerability of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM-HNSCC)**
Colevas, A. D., Kerrigan, K., Chin, V., Rainey, N., Park, J. J., Fang, B., Alpuim Costa, D., Dinis, J., Phan, M., Lin, L., Zhang, Y., Sun, S. C., Howland, et al
ELSEVIER SCIENCE INC.2024: E85-E86
 - **A Phase 1 Dose-escalation and Expansion Study of CUE 101, Given As Monotherapy in 3^{>rd} Line and in Combination with Pembrolizumab in 1^{>st} Line Recurrent/Metastatic (R/M) HPV16+Head and Neck Cancer Patients</sup></sup>**
Colevas, A. D., Chung, C. H., Adkins, D., Rodriguez, C. P., Park, J. C., Gibson, M. K., Sukari, A., Burtness, B., Johnson, F. M., Julian, R. A., Saba, N. F., Worden, F., Dunn, et al
ELSEVIER SCIENCE INC.2024: E87
 - **Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK-2019, a selective EBNA1 inhibitor. *Biomedical chromatography : BMC***
Davis, M. T., Anders, N. M., Colevas, A. D., Messick, T. E., Rudek, M. A.
2023: e5775
 - **A phase Ib/II study of nanatinostat (Nstat) plus valganciclovir (VGCV) in EBV plus solid tumors and with pembrolizumab (PEM) in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)**

Colevas, A. D., Siu, L., Lim, D., Gao, B., Voon, P., Khan, S., Eng, L., Ahn, M., Lee, V., Wang, H. M., Yang, M., Bowles, D., Ferrarotto, et al
ELSEVIER.2023: S1607

- **7-UP: Generating in silico CODEX from a small set of immunofluorescence markers.** *PNAS nexus*
Wu, E., Trevino, A. E., Wu, Z., Swanson, K., Kim, H. J., D'Angio, H. B., Preska, R., Chiou, A. E., Charville, G. W., Dalerba, P., Duvvuri, U., Colevas, A. D., Levi, et al
2023; 2 (6): pgad171
- **Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.**
Tang, L., Liu, L., Liu, H., Huang, Y., Jin, F., Xie, S., Li, Y., Guo, S., Li, X., Chen, D., Qi, B., Yang, J., Sun, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC)**
Sun, L., Cohen, R. B., Colevas, A.
LIPPINCOTT WILLIAMS & WILKINS.2023: 6039
- **Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus-positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies.**
Colevas, A., Rudek, M. A., Even, C., Lee, V., Gillison, M. L., Khan, S. A., Lu, R., Winters, E., Biedermann, S., Lai, S., Messick, T.
LIPPINCOTT WILLIAMS & WILKINS.2023: 6035
- **A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC**
Colevas, A., Dinis, J., Chin, V. T., Costa, D., Park, J. J., Fang, B., Phan, M., Zhang, Y., U'Ren, L., Odegard, J., Curtis, K., Pirtle, E., Adkins, et al
LIPPINCOTT WILLIAMS & WILKINS.2023: TPS6102
- **A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+head and neck cancer.**
Chung, C. H., Colevas, A., Adkins, D., Rodriguez, C. P., Park, J., Gibson, M. K., Burtneess, B., Johnson, F. M., Julian, R., Saba, N. F., Worden, F. P., Dunn, L., Seiwert, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **A novel mitochondrial-targeted [18F]F-AraG positron emission tomography (PET) biomarker for early diagnosis and monitoring of cardiotoxicity**
Shrestha, U., Chae, H., Blecha, J., Colevas, A., Sunwoo, J., VanBrocklin, H., Levi, J., Seo, Y.
SOC NUCLEAR MEDICINE INC.2023
- **Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC).**
Sun, L., Cohen, R. B., Colevas, A.
LIPPINCOTT WILLIAMS & WILKINS.2023
- **A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC**
Colevas, A., Dinis, J., Chin, V. T., Costa, D., Park, J. J., Fang, B., Phan, M., Zhang, Y., U'Ren, L., Odegard, J., Curtis, K., Pirtle, E., Adkins, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus-positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies.**
Colevas, A., Rudek, M. A., Even, C., Lee, V., Gillison, M. L., Khan, S. A., Lu, R., Winters, E., Biedermann, S., Lai, S., Messick, T.
LIPPINCOTT WILLIAMS & WILKINS.2023
- **A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+head and neck cancer.**
Chung, C. H., Colevas, A., Adkins, D., Rodriguez, C. P., Park, J., Gibson, M. K., Burtneess, B., Johnson, F. M., Julian, R., Saba, N. F., Worden, F. P., Dunn, L., Seiwert, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cis-platin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.**

Tang, L., Liu, L., Liu, H., Huang, Y., Jin, F., Xie, S., Li, Y., Guo, S., Li, X., Chen, D., Qi, B., Yang, J., Sun, et al
LIPPINCOTT WILLIAMS & WILKINS.2023

- **Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled Trial.** *JAMA network open*
Lee, N. Y., Harris, J., Kim, J., Garden, A., Mechalakos, J., Pfister, D. G., Chan, A. T., Hu, K., Colevas, A. D., Frank, S., Shenouda, G., Bar-Ad, V., Waldron, et al
2023; 6 (6): e2316094
- **In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation.** *PloS one*
Jun, M., Pinto, H., Le, Q. T., Quon, A., Hara, W., Coty, J., McMillan, A., Lu, R., Winters, E., Lira, R., Colevas, A. D.
2023; 18 (2): e0276651
- **Immunotherapy for Keratinocyte Cancers. Part 1: Immune-Related Epidemiology, Risk Factors, Pathogenesis, and Immunotherapy Management of Keratinocytic Cancers** *Journal of the American Academy of Dermatology*
Neuner, R., Lee, J., Park, C., Rieger, K. E., Colevas, A. D., Chang, A. S.
2023; 88 (6): 1225-1240
- **Safety of nivolumab added to chemoradiotherapy platforms for intermediate and high-risk local-regionally advanced head and neck squamous cell carcinoma: RTOG Foundation 3504.** *International journal of radiation oncology, biology, physics*
Gillison, M. L., Ferris, R. L., Harris, J., Colevas, A. D., Mell, L. K., Kong, C., Jordan, R. C., Moore, K. L., Truong, M., Kirsch, C., Chakravarti, A., Blakaj, D. M., Clump, et al
2022
- **⁸⁹Zr-panitumumab combined with ¹⁸F-FDG-PET improves detection and staging of head and neck squamous cell carcinoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Lee, Y., van den Berg, N. S., Duan, H., Azevedo, E. C., Ferri, V., Hom, M., Raymundo, R. C., Valencia, A., Castillo, J., Shen, B., Zhou, Q., Freeman, L., Koran, et al
2022
- **Posttreatment FDG-PET/CT Hopkins criteria predict locoregional recurrence after definitive radiotherapy for oropharyngeal squamous cell carcinoma.** *Head & neck*
Miller, J. A., Moradi, F., Sundaram, V., Liang, R., Zhang, C., Nguyen, N. K., Akhtar, F., Liu, Y., Ren, Y., Harandi, N., Weng, Y., Pollom, E. L., Colevas, et al
2022
- **HPV DNA as a biomarker in oropharyngeal cancer: A step in the right direction.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Colevas, A. D.
2022
- **Immune-related adverse effects of long-term PD-1/PD-L1 inhibitor treatment**
Kim, S., Colevas, A., Tse, S., On, S., Cheung, E.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+head and neck cancer.**
Chung, C. H., Colevas, A., Adkins, D., Gibson, M. K., Rodriguez, C. P., Sukari, A., Bauman, J. E., Wirth, L. J., Johnson, F. M., Saba, N. F., Burtness, B., Dunn, L., Seiwert, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **A phase 1b/2 study of nanatinostat and valganciclovir in patients with advanced Epstein-Barr virus positive (EBV+) solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC).**
Colevas, A., Siu, L. L., Lim, D., Gao, B., Rojkjaer, L., Katkov, A., Katz, Y., Ma, B.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **A randomized, controlled, open-label, phase 2 study of cemiplimab +/- RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).**
Haydon, A., Khushalani, N. I., Robert, C., Brungs, D., Collichio, F. A., Colevas, A., Lim, A., Kudchadkar, R., Chai-Ho, W., Daniels, G. A., Lutzky, J., Lee, J. H. J., Silk, et al
LIPPINCOTT WILLIAMS & WILKINS.2022

- **A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.** *Investigational new drugs*
McLean, L. S., Morris, T. A., Gramza, A., Liu, S., Khan, S. A., Colevas, A. D., Pearce, T., Rischin, D.
2022
- **A Phase 2 Study of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma**
Colevas, A. D., Park, J. J., Fang, B., Shao, J., U'Ren, L., Odegard, J., Lal, I., Phan, M., Thein, K. Z., Adkins, D.
ELSEVIER SCIENCE INC.2022: E42-E43
- **Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.** *The oncologist*
Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, et al
2022; 27 (2): e194-e198
- **Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141** *ONCOLOGIST*
Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Docampo, et al
2022; 27 (2): E194-E198
- **Skull base osteomyelitis in patients with head and neck cancer: Diagnosis, management, and outcomes in a case series of 23 patients.** *Laryngoscope investigative otolaryngology*
Czech, M. M., Hwang, P. H., Colevas, A. D., Fischbein, N., Ho, D. Y.
2022; 7 (1): 47-59
- **Skull base osteomyelitis in patients with head and neck cancer: Diagnosis, management, and outcomes in a case series of 23 patients** *LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY*
Czech, M. M., Hwang, P. H., Colevas, A., Fischbein, N., Ho, D. Y.
2022
- **Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam-Trastuzumab Deruxtecan.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Shukla, N. D., Chiang, R. S., Colevas, A. D.
2022; 20 (2): 102-104
- **NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2022.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Caudell, J. J., Gillison, M. L., Maghami, E., Spencer, S., Pfister, D. G., Adkins, D., Birkeland, A. C., Brizel, D. M., Busse, P. M., Cmelak, A. J., Colevas, A. D., Eisele, D. W., Galloway, et al
2022; 20 (3): 224-234
- **Post-Treatment FDG-PET/CT Hopkins Criteria Predict Locoregional Recurrence After Definitive Radiotherapy for Oropharyngeal Squamous Cell Carcinoma.** *International journal of radiation oncology, biology, physics*
Miller, J. A., Moradi, F., Liang, R., Zhang, C., Nguyen, N., Akhtar, F., Harandi, N. K., Colevas, A. D., Divi, V., Holsinger, F. C., Beadle, B. M., Le, Q. T., Gensheimer, et al
2021; 111 (3S): e399
- **A PHASE 1 TRIAL OF CUE-101, A NOVEL HPV16 E7-PHLA-IL2-FC FUSION PROTEIN, ALONE AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/METASTATIC HPV16+HEAD AND NECK CANCER**
Chung, C., Colevas, A., Gibson, M., Adkins, D., Sukari, A., Wirth, L., Burtness, B., Bauman, J., Rodriguez, C., Worden, F., Saba, N., Glisson, B., Dunn, et al
BMJ PUBLISHING GROUP.2021: A468
- **Post-Treatment FDG-PET/CT Hopkins Criteria Predict Locoregional Recurrence After Definitive Radiotherapy for Oropharyngeal Squamous Cell Carcinoma**
Miller, J. A., Moradi, F., Liang, R., Zhang, C., Nguyen, N., Akhtar, F., Harandi, N. K., Colevas, A. D., Divi, V., Holsinger, F. C., Beadle, B. M., Le, Q. T., Gensheimer, et al
ELSEVIER SCIENCE INC.2021: E399
- **AI-ASSISTED WHOLE-BODY ASSESSMENT OF IMMUNOTHERAPY RESPONSE USING [18F]F-ARAG, A PET AGENT FOR ACTIVATED T CELLS**
Levi, J., Perk, T., Huynh, L., Packiasamy, J., Cheng, S., Sunwoo, J., Colevas, A.

BMJ PUBLISHING GROUP.2021: A52

- **Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Lansinger, O. M., Biedermann, S., He, Z., Colevas, A. D.
2021: JCO2101200
- **Pan-cancer survey of HLA loss of heterozygosity using a robustly validated NGS-based machine learning algorithm.**
Pyke, R., Mellacheruvu, D., Abbott, C., Dea, S., Levy, E., Zhang, S. V., Bedi, N., Colevas, A., Bhave, D., Chinnappa, M., Bartha, G., Lyle, J., West, et al
AMER ASSOC CANCER RESEARCH.2021
- **Longitudinal exome-scale liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy.**
Abbott, C. W., Bedi, N., Zhang, S. V., Northcott, J., Li, R., Pyke, R., Levy, E., Chernock, R., Mansour, M., Colevas, A., Lyle, J., Sunwoo, J. B., Boyle, et al
AMER ASSOC CANCER RESEARCH.2021
- **Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW.** *Theranostics*
Krishnan, G., van den Berg, N. S., Nishio, N., Juniper, G., Pei, J., Zhou, Q., Lu, G., Lee, Y. J., Ramos, K., Iagaru, A. H., Baik, F. M., Colevas, A. D., Martin, et al
2021; 11 (15): 7188-7198
- **Association of HLA loss of heterozygosity with allele-specific neoantigen expansion in response to immunotherapy.**
Pyke, R., Abbott, C., Dea, S., Bedi, N., Colevas, A., Levy, E., Zhang, S. V., Snyder, M., Mellacheruvu, D., Sunwoo, J. B., Chen, R., Boyle, S.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Treatment patterns for patients with metastatic or recurrent head and neck cancer in a large integrated health-care system.**
Seto, T., Samant, N. D., Shah, N., Shirazi, A., Colevas, A., Katzel, J.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Intraoperative Fluorescence-Guided Surgery in Head and Neck Squamous Cell Carcinoma.** *The Laryngoscope*
Lee, Y. J., Krishnan, G., Nishio, N., van den Berg, N. S., Lu, G., Martin, B. A., van Keulen, S., Colevas, A. D., Kapoor, S., Liu, J. T., Rosenthal, E. L.
2021; 131 (3): 529-534
- **Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.** *JACC. CardioOncology*
Waliyany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., Padda, S. K., Fan, A. C., Colevas, A. D., Wu, S. M., Witteles, R. M., Zhu, H.
2021; 3 (1): 137-39
- **Unambiguous advanced radiologic extranodal extension determined by MRI predicts worse outcomes in nasopharyngeal carcinoma: Potential improvement for future editions of N category systems.** *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*
Mao, Y., Wang, S., Lydiatt, W., Shah, J. P., Colevas, A. D., Lee, A. W., O'Sullivan, B., Guo, R., Luo, W., Chen, Y., Tian, L., Tang, L., Sun, et al
2021
- **Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Chen, Y., Ismaila, N., Chua, M. L., Colevas, A. D., Haddad, R., Huang, S. H., Wee, J. T., Whitley, A. C., Yi, J., Yom, S. S., Chan, A. T., Hu, C., Lang, et al
2021: JCO2003237
- **Postoperative Observation Versus Radiotherapy for Pathologic N1 Oral Cavity Squamous Cell Carcinoma.** *American journal of clinical oncology*
Xiang, M. n., Holsinger, F. C., Gensheimer, M. F., Divi, V. n., Pollom, E. L., Colevas, A. D., Le, Q. T., Beadle, B. M.
2021; Publish Ahead of Print
- **Genome Sequencing and Apoptotic Markers to Assess Treatment Response of Lacrimal Gland Adenoid Cystic Carcinoma to Intra-Arterial Cytoreductive Chemotherapy.** *Ophthalmic plastic and reconstructive surgery*
Yu, M. D., Men, C. J., Do, H., Colevas, A. D., Lin, J. H., Egbert, P. R., Tse, D. T., Kossler, A. L.
2021

- **A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]**
Haydon, A. M., Alamgeer, M., Brungs, D., Collichio, F., Khushalani, N. I., Colevas, A. D., Rischin, D., Kudchadkar, R., Chai-Ho, W., Daniels, G., Lutzky, J., Lee, J. H., Bowyer, et al
ELSEVIER.2021: S904
- **Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW THERANOSTICS**
Krishnan, G., van den Berg, N. S., Nishio, N., Juniper, G., Pei, J., Zhou, Q., Lu, G., Lee, Y., Ramos, K., Iagaru, A. H., Baik, F. M., Colevas, A. D., Martin, et al
2021; 11 (15): 7188-7198
- **Treatment Breaks During Definitive Head/Neck Radiotherapy: Survival Impact and Predisposing Factors**
Xiang, M., Gensheimer, M., Pollom, E., Holsinger, F., Colevas, A., Quynh-Thu Le, Beadle, B.
ELSEVIER SCIENCE INC.2020: E39
- **Association Between Immunosuppression and Outcomes in Oral Cavity Squamous Cell Carcinoma. *Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery***
Chang, J., Sunwoo, J. B., Shah, J. L., Hara, W., Hong, J., Colevas, A. D., Divi, V.
2020: 194599820960146
- **Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma. *JAAD case reports***
Marukian, N. V., Lin, J. Q., Colevas, A. D., Coutre, S., Chang, A. L.
2020; 6 (9): 819–21
- **Sensitive HLA loss of heterozygosity detection reveals allele-specific neoantigen expansion as resistance mechanism to anti-PD-1 therapy**
Pyke, R., Abbott, C., Mellacheruvu, D., Zhang, S., Bedi, N., Colevas, A., Sunwoo, J., West, J., Chen, R., Boyle, S.
AMER ASSOC CANCER RESEARCH.2020
- **Intraoperative Fluorescence-Guided Surgery in Head and Neck Squamous Cell Carcinoma *LARYNGOSCOPE***
Lee, Y., Krishnan, G., Nishio, N., van den Berg, N. S., Lu, G., Martin, B. A., van Keulen, S., Colevas, A. D., Kapoor, S., Liu, J. T. C., Rosenthal, E. L.
2020
- **Head and Neck Cancers, Version 2.2020 *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK***
Pfister, D. G., Spencer, S., Adelstein, D., Adkins, D., Anzai, Y., Brizel, D. M., Bruce, J. Y., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A., Eisele, D. W., Fenton, et al
2020; 18 (7): 873–98
- **Radiotherapy plus cetuximab or cisplatin in human papilloma-virus positive oropharyngeal cancer (NRG 1016): A randomized multicenter noninferiority trial**
Ridge, J. A., Ringash, J., Yao, M., Blakaj, D. M., Razaq, M. A., Colevas, A. D., Beitler, J. J., Jones, C. U., Dunlap, N. E., Seaward, S. A., Spencer, S., Galloway, T. J., Dignam, et al
AMER ASSOC CANCER RESEARCH.2020: 21–22
- **Exome scale liquid biopsy characterization of putative neoantigens and genomic biomarkers pre- and post anti-PD-1 therapy in squamous cell carcinoma of the head and neck.**
Abbott, C., Bedi, N., Zhang, S., Li, R., Pyke, R., Levy, E., Chernock, R., Mansour, M., Sunwoo, J. B., Colevas, A., Chen, R., Boyle, S.
AMER SOC CLINICAL ONCOLOGY.2020
- **CT-based Radiomic Signatures for Predicting Histopathologic Features in Head and Neck Squamous Cell Carcinoma. *Radiology. Imaging cancer***
Mukherjee, P., Cintra, M., Huang, C., Zhou, M., Zhu, S., Colevas, A. D., Fischbein, N., Gevaert, O.
2020; 2 (3): e190039
- **Survival Benefit of Postoperative Radiotherapy in Pathological N1 Oral Cavity Squamous Cell Carcinoma**
Xiang, M., Holsinger, F. C., Gensheimer, M. F., Divi, V., Pollom, E., Colevas, A. D., Le, Q. T., Beadle, B. M.
ELSEVIER SCIENCE INC.2020: 1125
- **Exome scale liquid biopsy monitoring of putative neoantigens and genomic biomarkers in patients on anti-PD-1 therapy in squamous cell carcinoma of the head and neck.**
Abbott, C. W., Bedi, N., Zhang, S. V., Li, R., Pyke, R., Levy, E., Chernock, R., Mansour, M., Sunwoo, J. B., Colevas, A., Chen, R., Boyle, S. M.
AMER ASSOC CANCER RESEARCH.2020: 94–95

- **Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck Cancer** *MOLECULAR IMAGING AND BIOLOGY*
Nishio, N., van den Berg, N. S., van Keulen, S., Martin, B. A., Fakurnejad, S., Zhou, Q., Lu, G., Chirita, S. U., Kaplan, M. J., Divi, V., Colevas, A. D., Rosenthal, E. L.
2020; 22 (1): 156–64
- **Predicting Therapeutic Antibody Delivery into Human Head and Neck Cancers.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Lu, G., Fakurnejad, S., Martin, B. A., van den Berg, N. S., van Keulen, S., Nishio, N., Zhu, A. J., Chirita, S. U., Zhou, Q., Gao, R. W., Kong, C. S., Fischbein, N., Penta, et al
2020
- **Prolongation of definitive head and neck cancer radiotherapy: Survival impact and predisposing factors.** *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*
Xiang, M. n., Gensheimer, M. F., Pollom, E. L., Holsinger, F. C., Colevas, A. D., Le, Q. T., Beadle, B. M.
2020
- **Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates.** *Nature communications*
Lu, G., Nishio, N., van den Berg, N. S., Martin, B. A., Fakurnejad, S., van Keulen, S., Colevas, A. D., Thurber, G. M., Rosenthal, E. L.
2020; 11 (1): 5667
- **Safety and Stability of Antibody-Dye Conjugate in Optical Molecular Imaging.** *Molecular imaging and biology*
Pei, J. n., Juniper, G. n., van den Berg, N. S., Nishio, N. n., Broadt, T. n., Welch, A. R., Yi, G. S., Raymundo, R. C., Chirita, S. U., Lu, G. n., Krishnan, G. n., Lee, Y. J., Kapoor, et al
2020
- **Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance.** *The Journal of clinical investigation*
Nambiar, D. K., Aguilera, T., Cao, H., Kwok, S., Kong, C., Bloomstein, J., Wang, Z., Rangan, V. S., Jiang, D., von Eyben, R., Liang, R., Agarwal, S., Colevas, et al
2019
- **Optical molecular imaging can differentiate metastatic from benign lymph nodes in head and neck cancer.** *Nature communications*
Nishio, N., van den Berg, N. S., van Keulen, S., Martin, B. A., Fakurnejad, S., Teraphongphom, N., Chirita, S. U., Oberhelman, N. J., Lu, G., Horton, C. E., Kaplan, M. J., Divi, V., Colevas, et al
2019; 10 (1): 5044
- **Assessing Care Value for Older Patients Receiving Radiotherapy With or Without Cisplatin or Cetuximab for Locoregionally Advanced Head and Neck Cancer.** *JAMA otolaryngology-- head & neck surgery*
Saraswathula, A., Chen, M. M., Colevas, A. D., Divi, V.
2019
- **Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment.** *Head & neck*
Nishio, N., van Keulen, S., van den Berg, N. S., Lu, G., LaRochelle, E. P., Davis, S. C., Martin, B. A., Fakurnejad, S., Zhou, Q., Birkeland, A. C., Kaplan, M. J., Divi, V., Colevas, et al
2019
- **Fluorescence molecular imaging for identification of high-grade dysplasia in patients with head and neck cancer.** *Oral oncology*
Fakurnejad, S., van Keulen, S., Nishio, N., Engelen, M., van den Berg, N. S., Lu, G., Birkeland, A., Baik, F., Colevas, A. D., Rosenthal, E. L., Martin, B. A.
2019; 97: 50–55
- **Cost comparison of treatment for oropharyngeal carcinoma** *LARYNGOSCOPE*
Tam, K., Orosco, R. K., Colevas, A., Bedi, N., Starmer, H. M., Beadle, B. M., Holsinger, F.
2019; 129 (7): 1604–9
- **Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Le, Q., Colevas, A., OSullivan, B., Lee, A. W. M., Lee, N., Ma, B., Siu, L. L., Waldron, J., Lim, C., Riaz, N., Lynn, J., Malik, S.
2019; 111 (7): 655–63

- **Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.** *Cancer*
Haddad, R., Concha-Benavente, F., Blumenschein, G. J., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Kasper, S., Vokes, E. E., Worden, F., Saba, N. F., Tahara, M., Jayaprakash, et al
2019
- **Nivolumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Ferris, R. L., Licitra, L., Fayette, J., Even, C., Blumenschein, G. R., Harrington, K. J., Guigay, J., Vokes, E. E., Saba, N. F., Haddad, R. I., Ramkumar, S., Russell, J., Brossart, et al
2019
- **The Clinical Application of Fluorescence-Guided Surgery in Head and Neck Cancer** *JOURNAL OF NUCLEAR MEDICINE*
van Keulen, S., Nishio, N., Fakurnejad, S., Birkeland, A., Martin, B. A., Lu, G., Zhou, Q., Chirita, S. U., Forouzanfar, T., Colevas, A., van den Berg, N. S., Rosenthal, E. L.
2019; 60 (6): 758–63
- **The Sentinel Margin: Intraoperative ex-vivo Specimen Mapping Using Relative Fluorescence Intensity.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
van Keulen, S., Nishio, N., Birkeland, A., Fakurnejad, S., Martin, B. A., Forouzanfar, T., Cunanan, K., Colevas, A. D., van den Berg, N. S., Rosenthal, E. L.
2019
- **Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504.**
Gillison, M. L., Ferris, R. L., Harris, J., Colevas, A., Mell, L. K., Kong, C., Jordan, R. C., Moore, K., Minh Tam Truong, Kirsch, C., Clump, D., Ohr, J., He, K., et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Tabelecleucel in combination with pembrolizumab (Pembro) in platinum-pretreated, recurrent/metastatic Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (EBV plus NPC).**
Siu, L. L., Bauml, J., Adkins, D., Colevas, A., Perez, C., Choe, J., Zhang, Y., Shi, W., Navarro, W. H., Haigentz, M., Rabinowits, G., Pfister, D. G.
AMER SOC CLINICAL ONCOLOGY.2019
- **Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck Cancer.** *Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging*
Nishio, N., van den Berg, N. S., van Keulen, S., Martin, B. A., Fakurnejad, S., Zhou, Q., Lu, G., Chirita, S. U., Kaplan, M. J., Divi, V., Colevas, A. D., Rosenthal, E. L.
2019
- **Pembrolizumab with or without vismodegib for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study**
Chang, A., Tran, D. C., Cannon, J., Li, S., Jeng, M., Rieger, K., Sarin, K. Y., Yost, K., Satpathy, A., Reddy, S., Colevas, A.
ELSEVIER SCIENCE INC.2019: S92
- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers** *JOURNAL OF CLINICAL ONCOLOGY*
Sikic, B., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
2019; 37 (12): 946+
- **Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy.** *Journal of the National Cancer Institute*
Thu Le, Q., Dimitrios Colevas, A., O'Sullivan, B., Lee, A. W., Lee, N., Ma, B., Siu, L. L., Waldron, J., Lim, C., Riaz, N., Lynn, J., Malik, S.
2019
- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A. D., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
2019: JCO1802018

- **The Clinical Application of Fluorescence-Guided Surgery in Head and Neck Cancer.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
van Keulen, S., Nishio, N., Fakurnejad, S., Birkeland, A., Martin, B. A., Lu, G., Zhou, Q., Chirita, S. U., Forouzanfar, T., Colevas, D., van den Berg, N. S., Rosenthal, E. L.
2019
- **Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Chang, A. S., Tran, D. C., Cannon, J. G. D., Li, S., Jeng, M., Patel, R., Van der Bokke, L., Pague, A., Brotherton, R., Rieger, K. E., Satpathy, A. T., Yost, K. E., Reddy, et al
2019; 80 (2): 564–66
- **Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial** *LANCET*
Gillison, M. L., Trotti, A. M., Harris, J., Eisbruch, A., Harari, P. M., Adelstein, D. J., Sturgis, E. M., Burtness, B., Ridge, J. A., Ringash, J., Galvin, J., Yao, M., Koyfman, et al
2019; 393 (10166): 40–50
- **Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Xiang, M. n., Colevas, A. D., Holsinger, F. C., Le, Q. X., Beadle, B. M.
2019; 17 (9): 1065–73
- **Intraoperative Tumor Assessment Using Real-Time Molecular Imaging in Head and Neck Cancer Patients.** *Journal of the American College of Surgeons*
Keulen, S. v., Nishio, N. n., Fakurnejad, S. n., van den Berg, N. S., Lu, G. n., Birkeland, A. n., Martin, B. A., Forouzanfar, T. n., Dimitrios Colevas, A. n., Rosenthal, E. L.
2019
- **Rapid, non-invasive fluorescence margin assessment: Optical specimen mapping in oral squamous cell carcinoma.** *Oral oncology*
van Keulen, S., van den Berg, N. S., Nishio, N., Birkeland, A., Zhou, Q., Lu, G., Wang, H., Middendorf, L., Forouzanfar, T., Martin, B. A., Colevas, A. D., Rosenthal, E. L.
2019; 88: 58–65
- **Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy** *ANNALS OF ONCOLOGY*
Chen, Y., Wang, Y., Lv, J., Li, Y., Chua, M. K., Le, Q., Lee, N., Colevas, A., Seiwert, T., Hayes, D. N., Riaz, N., Vermorken, J. B., O'Sullivan, et al
2019; 30 (1): 68–75
- **Rapid, non-invasive fluorescence margin assessment: Optical specimen mapping in oral squamous cell carcinoma** *ORAL ONCOLOGY*
van Keulen, S., van den Berg, N. S., Nishio, N., Birkeland, A., Zhou, Q., Lu, G., Wang, H., Middendorf, L., Forouzanfar, T., Martin, B. A., Colevas, A., Rosenthal, E. L.
2019; 88: 58–65
- **PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma** *OTOLARYNGOLOGY-HEAD AND NECK SURGERY*
Amoils, M., Kim, J., Lee, C., Sunwoo, J. B., Colevas, A., Aasi, S. Z., Hollmig, S., Ma, Y., Divi, V.
2019; 160 (1): 93–99
- **Development and validation of radiomic signatures of head and neck squamous cell carcinoma molecular features and subtypes.** *EBioMedicine*
Huang, C. n., Cintra, M. n., Brennan, K. n., Zhou, M. n., Colevas, A. D., Fischbein, N. n., Zhu, S. n., Gevaert, O. n.
2019
- **Intraoperative Molecular Imaging for ex vivo Assessment of Peripheral Margins in Oral Squamous Cell Carcinoma.** *Frontiers in oncology*
Fakurnejad, S. n., Krishnan, G. n., van Keulen, S. n., Nishio, N. n., Birkeland, A. C., Baik, F. M., Kaplan, M. J., Colevas, A. D., van den Berg, N. S., Rosenthal, E. L., Martin, B. A.
2019; 9: 1476
- **NRG-RTOG 1016: Phase III Trial Comparing Radiation/Cetuximab to Radiation/Cisplatin in HPV-related Cancer of the Oropharynx**
Trotti, A., Harris, J., Gillison, M., Eisbruch, A., Harari, P. M., Adelstein, D. J., Sturgis, E. M., Galvin, J. M., Koyfman, S., Blakaj, D., Razaq, M. A., Colevas, A. D., Beitler, et al

ELSEVIER SCIENCE INC.2018: 1604–5

- **Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis** *CANCER*
Xiang, M., Holsinger, F., Colevas, A., Chen, M. M., Quynh-Thu Le, Beadle, B. M.
2018; 124 (23): 4486–94
- **Cost comparison of treatment for oropharyngeal carcinoma.** *The Laryngoscope*
Tam, K., Orosco, R. K., Dimitrios Colevas, A., Bedi, N., Starmer, H. M., Beadle, B. M., Christopher Holsinger, F.
2018
- **Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.** *Lancet (London, England)*
Gillison, M. L., Trotti, A. M., Harris, J., Eisbruch, A., Harari, P. M., Adelstein, D. J., Sturgis, E. M., Burtness, B., Ridge, J. A., Ringash, J., Galvin, J., Yao, M., Koyfman, et al
2018
- **Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Chen, Y., Wang, Y., Lv, J., Li, Y., Chua, M. L., Le, Q., Lee, N., Colevas, A. D., Seiwert, T., Hayes, D. N., Riaz, N., Vermorken, J. B., O'Sullivan, et al
2018
- **Cisplatin or Carboplatin-Based Chemoradiation for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Population-Based Comparison**
Xiang, M., Holsinger, F. C., Colevas, A. D., Hara, W., Le, Q. T., Beadle, B. M.
ELSEVIER SCIENCE INC.2018: E371
- **Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis.** *Cancer*
Xiang, M., Holsinger, F. C., Colevas, A. D., Chen, M. M., Le, Q., Beadle, B. M.
2018
- **Safety and Clinical Activity of Atezolizumab in Head and Neck Cancer: Results From a Phase I Trial.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Colevas, A. D., Bahleda, R., Braiteh, F., Balmanoukian, A., Brana, I., Chau, N. G., Sarkar, I., Molinero, L., Grossman, W., Kabbinar, F., Fasso, M., O'Hear, C., Powderly, et al
2018
- **Survival benefit of post-operative chemotherapy for intermediate-risk advanced stage head and neck cancer differs with patient age** *ORAL ONCOLOGY*
Chen, M. M., Colevas, A., Megwalu, U., Divi, V.
2018; 84: 71–75
- **CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer** *ONCOLOGIST*
Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Docampo, et al
2018; 23 (9): 1079–82
- **Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence** *CANCER RESEARCH*
Gao, R. W., Teraphongphom, N. T., van den Berg, N. S., Martin, B. A., Oberhelman, N. J., Divi, V., Kaplan, M. J., Hong, S. S., Lu, G., Ertsey, R., Tummers, W. J., Gomez, A. J., Holsinger, et al
2018; 78 (17): 5144–54
- **A case of combination PD-1 inhibitor and intralesional 5-fluorouracil for high-frequency nonmelanoma skin cancers in an immunocompromised patient**
Duy Tran, Lee, C., Colevas, A., Chang, A.
MOSBY-ELSEVIER.2018: AB6
- **Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence.** *Cancer research*
Gao, R. W., Teraphongphom, N. T., van den Berg, N. S., Martin, B. A., Oberhelman, N. J., Divi, V., Kaplan, M. J., Hong, S. S., Lu, G., Ertsey, R., Tummers, W. S., Gomez, A. J., Holsinger, et al

2018

- **PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.** *Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery*
Amoils, M., Kim, J., Lee, C., Sunwoo, J. B., Colevas, A. D., Aasi, S. Z., Hollmig, S. T., Ma, Y., Divi, A. V.
2018: 194599818788057
- **Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141**
Ferris, R. L., Blumenschein, G. R., Fayette, J., Guigay, J., Colevas, A., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Docampo, et al
AMER ASSOC CANCER RESEARCH.2018
- **Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck** *ONCOLOGIST*
Trieu, V., Pinto, H., Riess, J. W., Lira, R., Luciano, R., Coty, J., Boothroyd, D., Colevas, A.
2018; 23 (7): 764-+
- **Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression** *ORAL ONCOLOGY*
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, et al
2018; 81: 45-51
- **Comparative Effectiveness and Toxicity of Cetuximab or Cisplatin With Concurrent Radiation for Locoregionally Advanced Squamous Cell Carcinoma of The Head And Neck: A Population-Based Analysis**
Xiang, M., Holsinger, F., Chen, M., Colevas, A., Beadle, B.
ELSEVIER SCIENCE INC.2018: E16
- **A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.**
Sikic, B. I., Lakhani, N. J., Patnaik, A., Shah, S., Chandana, S. R., Rasco, D. W., Colevas, A., O'Rourke, T. J., Papadopoulos, K. P., Fisher, G. A., Chao, M., Agoram, B., Chen, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504.**
Ferris, R. L., Gillison, M. L., Harris, J., Colevas, A., Mell, L. K., Kong, C., Jordan, R., Moore, K., Truong, M., Kirsch, C., Clump, D., Ohr, J., He, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **NCCN Guidelines (R) Insights Head and Neck Cancers, Version 1.2018 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Colevas, A., Yom, S. S., Pfister, D. G., Spencer, S., Adelstein, D., Adkins, D., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Eisele, D. W., Fenton, et al
2018; 16 (5): 479-90
- **Comparative Effectiveness of Cetuximab or Cisplatin With Concomitant Radiation for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Population-Based Analysis**
Xiang, M., Holsinger, F. C., Chen, M. M., Colevas, A. D., Beadle, B. M.
ELSEVIER SCIENCE INC.2018: 1322
- **Safety Evaluation of Nivolumab Concomitant With Platinum-Based Chemoradiation therapy for Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504**
Gillison, M., Ferris, R. L., Zhang, Q., Colevas, A. D., Mell, L. K., Kirsch, C., Moore, K. L., Truong, M. T., Kong, C. S., Jordan, R., Clump, D. A., Ohr, J., He, et al
ELSEVIER SCIENCE INC.2018: 1307-8
- **Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups**
Ferris, R. L., Blumenschein, G. R., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Docampo, et al
ELSEVIER SCIENCE INC.2018: 1317

- **Panitumumab-IRDye800 as an Optical Agent for Image-Guided Surgery in Patients With Squamous Cell Carcinoma**
Gao, R. W., Teraphongphom, N., van den Berg, N. S., Hong, S., Martin, B. A., Divi, V., Kaplan, M. J., Ertsey, R., Oberhelman, N. J., Lu, G., Kong, C. S., Colevas, A. D., Rosenthal, et al
ELSEVIER SCIENCE INC.2018: 1312–13
- **Panitumumab-IRDye800 as an Optical Agent for Image-Guided Surgery in Patients With Squamous Cell Carcinoma**
Gao, R. W., Teraphongphom, N., van den Berg, N. S., Hong, S., Martin, B. A., Divi, V., Kaplan, M. J., Ertsey, R., Oberhelman, N. J., Lu, G., Kong, C. S., Colevas, A. D., Rosenthal, et al
ELSEVIER SCIENCE INC.2018: 1312–13
- **A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy** *JOURNAL OF THORACIC DISEASE*
Gubens, M. A., Chuang, J. C., Akerley, W., Langer, C. J., Clement-Duchene, C., San Pedro-Salcedo, M., Colevas, A., Dragnev, K., Socinski, M. A., Wakelee, H. A.
2018; 10 (1): 219–27
- **Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study.** *Journal of the American Academy of Dermatology*
Chang, A. L., Tran, D. C., Cannon, J. G., Li, S. n., Jeng, M. n., Patel, R. n., Van der Bokke, L. n., Pague, A. n., Brotherton, R. n., Rieger, K. E., Satpathy, A. T., Yost, K. E., Reddy, et al
2018
- **Nivolumab (Nivo) vs Investigator's Choice (IC) for Platinum-Refractory (PR) Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CheckMate 141): Outcomes in First-line (1L) R/M Patients (Pts) and Updated Safety and Efficacy**
Kasper, S., Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Docampo, et al
KARGER.2018: 96
- **Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers** *THERANOSTICS*
Gao, R. W., Teraphongphom, N., de Boer, E., van den Berg, N. S., Divi, V., Kaplan, M. J., Oberhelman, N. J., Hong, S. S., Capes, E., Colevas, A., Warram, J. M., Rosenthal, E. L.
2018; 8 (9): 2488–95
- **Nivolumab vs Investigator'S Choice (IC) in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use**
Ferris, R. L., Licitra, L., Fayette, J., Even, C., Blumenschein, G., Harrington, K. J., Guigay, J., Vokes, E. E., Saba, N. F., Haddad, R., Ramkumar, S., Russell, J., Brossart, et al
WILEY.2017: 143
- **Characterisation of Potential Predictive Biomarkers of Response to Nivolumab in Checkmate 141 in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)**
Concha-Benavente, F., Gillison, M. L., Blumenschein, G., Harrington, K. J., Fayette, J., Colevas, A., Licitra, L., Kasper, S., Even, C., Worden, F., Saba, N. F., Haddad, R., Tahara, et al
WILEY.2017: 141
- **Nivolumab Versus Investigator'S Choice (IC) for Platinum-Refractory Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CHECKMATE 141): Outcomes in First-Line R/M Patients and Updated Safety and Efficacy**
Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, et al
WILEY.2017: 144
- **Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes**
Haddad, R., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Kasper, S., Vokes, E. E., Worden, F., Saba, N. F., Tahara, M., Concha-Benavente, F., Monga, et al
OXFORD UNIV PRESS.2017
- **Commentary on "Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data"** *ONCOLOGIST*
Colevas, A.
2017; 22 (9): 1022–23

- **Treatment beyond progression with nivolumab (nivo) in patients with recurrent or metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the phase 3 CheckMate 141 study**
Kasper, S., Haddad, R., Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Vokes, E. E., Worden, F., Saba, N. F., Tahara, M., Monga, et al
KARGER.2017: 250+
- **Long-Term Safety and Clinical Outcomes of Atezolizumab in Head and Neck Cancer: Phase Ia Trial Results**
Bahleda, R., Braiteh, F. S., Balmanoukian, A. S., Brana, I., Hodi, F. S., Garbo, L., Liu, B., Molinero, L., O'Hear, C., Shen, X., Colevas, A. D.
OXFORD UNIV PRESS.2017
- **Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial LANCET ONCOLOGY**
Harrington, K. J., Ferris, R. L., Blumenschein, G., Colevas, A., Fayette, J., Licitra, L., Kasper, S., Even, C., Vokes, E. E., Worden, F., Saba, N. F., Kiyota, N., Haddad, et al
2017; 18 (8): 1104–15
- **PD-1 inhibition for cutaneous squamous cell carcinoma: A study of six consecutive cases**
Duy Tran, Colevas, A., Chang, A.
MOSBY-ELSEVIER.2017: AB193
- **NCCN Guidelines (R) Insights Head and Neck Cancers, Version 2.2017 JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK**
Adelstein, D., Gillison, M. L., Pfister, D. G., Spencer, S., Adkins, D., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A., Eisele, D. W., Fenton, et al
2017; 15 (6): 761–70
- **A randomized phase II study of chemoradiation (CRT) plus +/- nivolumab (Nivo) with sequential safety evaluations of Nivo plus +/- lirilumab (Liri) or ipilimumab (Ipi) concomitant with (C) RI in intermediate (IR) and high-risk (HR) head and neck squamous cell carcinoma (HNSCC) (RTOG 3504, NCT02764593).**
Gillison, M. L., Ferris, R. L., Zhang, Q., Colevas, A., Mell, L. K., Kong, C., Jordan, R., Moore, K., Truong, M., Kirsch, C., Machtay, M., Curran, W., Le, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN).**
Concha-Benavente, F., Gillison, M. L., Blumenschein, G. R., Harrington, K., Fayette, J., Colevas, A., Licitra, L., Kasper, S., Even, C., Worden, F. P., Saba, N. F., Haddad, R. I., Tahara, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **An open-label, single-arm, multi-institutional phase II trial of avelumab for recurrent, metastatic nasopharyngeal carcinoma.**
Sacco, A., Messer, K., Leidner, R. S., Colevas, A., Nieva, J. J., Chau, N., Nangia, C., Pinsky, B., Gold, K. A., Daniels, G. A., Cohen, E. E. W.
AMER SOC CLINICAL ONCOLOGY.2017
- **Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy. JAMA dermatology**
Freites-Martinez, A., Kwong, B. Y., Rieger, K. E., Coit, D. G., Colevas, A. D., Lacouture, M. E.
2017
- **E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx-ECOG-ACRIN Cancer Research Group AMERICAN JOURNAL OF PSYCHOLOGY**
Marur, S., Li, S., Cmelak, A. J., Gillison, M. L., Zhao, W. J., Ferris, R. L., Westra, W. H., Gilbert, J., Bauman, J. E., Wagner, L. I., Trevarthen, D. R., Balkrishna, J., Murphy, et al
2017; 130 (1): 490-U169
- **Node-positive cutaneous squamous cell carcinoma of the head and neck: Survival, high-risk features, and adjuvant chemoradiotherapy outcomes. Head & neck**
Amoils, M., Lee, C. S., Sunwoo, J., Aasi, S. Z., Hara, W., Kim, J., Sirjani, D., Colevas, A. D., Chang, A. L., Divi, V.
2017
- **Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN).**

Ferris, R. L., Concha-Benavente, F., Blumenschein, G. R., Harrington, K. J., Fayette, J., Colevas, A., Licitra, L. F., Kasper, S., Even, C., Gillison, M. L., Worden, F., Saba, N. F., Haddad, et al
AMER SOC CLINICAL ONCOLOGY.2017

- **Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy** *ANNALS OF ONCOLOGY*
MAKKOUK, A., Sundaram, V., Chester, C., Chang, S., Colevas, A. D., Sunwoo, J. B., Maecker, H., Desai, M., Kohrt, H. E.
2017; 28 (2): 415-420
- **E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.** *Journal of clinical oncology*
Marur, S., Li, S., Cmelak, A. J., Gillison, M. L., Zhao, W. J., Ferris, R. L., Westra, W. H., Gilbert, J., Bauman, J. E., Wagner, L. I., Trevarthen, D. R., Balkrishna, J., Murphy, et al
2016: JCO2016683300-?
- **Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.** *Cancer*
Pan, J. J., Ng, W. T., Zong, J. F., Lee, S. W., Choi, H. C., Chan, L. L., Lin, S. J., Guo, Q. J., Sze, H. C., Chen, Y. B., Xiao, Y. P., Kan, W. K., O'Sullivan, et al
2016; 122 (21): 3307-3315
- **Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck** *NEW ENGLAND JOURNAL OF MEDICINE*
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, et al
2016; 375 (19): 1856-1867
- **Characterizing CD137 Upregulation on NK cells in Patients Receiving Monoclonal Antibody Therapy.** *Annals of oncology*
MAKKOUK, A., Sundaram, V., Chester, C., Chang, S., Colevas, A. D., Sunwoo, J. B., Maecker, H., Desai, M., Kohrt, H. E.
2016
- **Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.** *JAMA dermatology*
Tran, D. C., Colevas, A. D., Chang, A. L.
2016
- **A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.** *Investigational new drugs*
Rosen, L. S., LoRusso, P., Ma, W. W., Goldman, J. W., Weise, A., Colevas, A. D., Adjei, A., Yazji, S., Shen, A., Johnston, S., Hsieh, H., Chan, I. T., Sikic, et al
2016; 34 (5): 604-613
- **BRAF inhibitor therapy of primary ameloblastoma** *ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY*
Tan, S., Pollack, J. R., Kaplan, M. J., Colevas, A., West, R. B.
2016; 122 (4): 518-19
- **Design and rationale of a prospective, multi-institutional registry for patients with sinonasal malignancy.** *Laryngoscope*
Beswick, D. M., Holsinger, F. C., Kaplan, M. J., Fischbein, N. J., Hara, W., Colevas, A. D., Le, Q., Berry, G. J., Hwang, P. H.
2016; 126 (9): 1977-1980
- **Ameloblastoma: a clinical review and trends in management** *EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY*
McClary, A. C., West, R. B., McClary, A. C., Pollack, J. R., Fischbein, N. J., Holsinger, C. F., Sunwoo, J., Colevas, A. D., Sirjani, D.
2016; 273 (7): 1649-1661
- **BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response** *ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY*
Tan, S., Pollack, J. R., Kaplan, M. J., Colevas, A. D., West, R. B.
2016; 122 (1): E5-E7
- **Third party assessment of resection margin status in head and neck cancer.** *Oral oncology*
Ransohoff, A., Wood, D., Solomon Henry, A., Divi, V., Colevas, A.
2016; 57: 27-31
- **Third party assessment of resection margin status in head and neck cancer** *ORAL ONCOLOGY*

- Ransohoff, A., Wood, D., Henry, A. S., Divi, V., Colevas, A.
2016; 57: 27-31
- **Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer** *CURRENT TREATMENT OPTIONS IN ONCOLOGY*
Narayanan, S., Colevas, A. D.
2016; 17 (6)
 - **A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers**
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
AMER SOC CLINICAL ONCOLOGY.2016
 - **Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.**
Ferris, R. L., Blumenschein, G. R., Fayette, J., Guigay, J., Colevas, A., Licitra, L. F., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F. P., Haddad, R. I., Kiyota, et al
AMER SOC CLINICAL ONCOLOGY.2016
 - **A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).**
Rischin, D., Boyer, M. J., Brzezniak, C. E., Colevas, A., Doebele, R., Gilbert, J., Gitlitz, B., Khan, S. A., Mehra, R., Seiwert, T. Y., Kroll, S., Pearce, T. E., Liu, et al
AMER SOC CLINICAL ONCOLOGY.2016
 - **Number of positive nodes is superior to the lymph node ratio and American Joint Committee on Cancer N staging for the prognosis of surgically treated head and neck squamous cell carcinomas** *CANCER*
Roberts, T. J., Colevas, A. D., Hara, W., Holsinger, F. C., Oakley-Girvan, I., Divi, V.
2016; 122 (9): 1388-1397
 - **Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.** *JAMA dermatology*
Ally, M. S., Ransohoff, K., Sarin, K., Atwood, S. X., Rezaee, M., Bailey-Healy, I., Kim, J., Beachy, P. A., Chang, A. L., Oro, A., Tang, J. Y., Colevas, A. D.
2016; 152 (4): 452-456
 - **Regionally Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck: Survival and High-Risk Features**
Amoils, M., Lee, C. S., Sunwoo, J., Aasi, S. Z., Hara, W., Kim, J., Sirjani, D., Colevas, A. D., Chang, A. S., Divi, V.
ELSEVIER SCIENCE INC.2016: 954
 - **A Pilot Study of Electronic Quality of Life Assessments Using Tablet Devices During and After Treatment of Head and Neck Cancers**
Wang, E., Pollom, E., Bui, T., Ognibene, G., von Eyben, R., Divi, V., Sunwoo, J., Kaplan, M., Colevas, A. D., Le, Q. T., Hara, W.
ELSEVIER SCIENCE INC.2016: 969
 - **Prognostic Value of Lymph Node Status Is Greater Than Lymph Node Ratio and AJCC N Staging for Head and Neck Squamous Cell Carcinomas**
Roberts, T., Colevas, A. D., Hara, W., Holsinger, F. C., Oakley-Girvan, I., Divi, V.
ELSEVIER SCIENCE INC.2016: 911-12
 - **Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.** *Cancer*
Pan, J. J., Ng, W. T., Zong, J. F., Chan, L. L., O'Sullivan, B., Lin, S. J., Sze, H. C., Chen, Y. B., Choi, H. C., Guo, Q. J., Kan, W. K., Xiao, Y. P., Wei, et al
2016; 122 (4): 546-558
 - **Discordance in routine second opinion pathology review of head and neck oncology specimens: A single-center five year retrospective review** *ORAL ONCOLOGY*
Zhu, G. A., Lira, R., Colevas, A. D.
2016; 53: 36-41
 - **Discordance in routine second opinion pathology review of head and neck oncology specimens: A single-center five year retrospective review.** *Oral oncology*
Zhu, G. A., Lira, R., Colevas, A. D.

2016; 53: 36-41

- **Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma** *JAMA Dermatology*
Sarin, K. Y., Ally, M. S., Ransohoff, K. J., Atwood, S. X., Rezaee, M.
2016: 1-5
- **Design and rationale of a prospective multi-institutional registry for patients with sinusoidal malignancy** *The Laryngoscope*
Beswick, D. M., Holsinger, F. C., Kaplan, M. J., Fischbein, N. J., Hara, W. Y., Colevas, A. D., Le, Q. T., Berry, G. J., Hwang, P. H.
2016
- **A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor** *JAMA DERMATOLOGY*
Chang, A. S., Kim, J., Luciano, R., Sullivan-Chang, L., Colevas, A. D.
2016; 152 (1): 106-8
- **A prospective study of electronic quality of life assessment using tablet devices during and after treatment of head and neck cancers.** *Oral oncology*
Pollom, E. L., Wang, E., Bui, T. T., Ognibene, G., von Eyben, R., Divi, V., Sunwoo, J., Kaplan, M., Dimitri Colevas, A., Le, Q., Hara, W. Y.
2015; 51 (12): 1132-1137
- **New Diseases and New Treatments-Head and Neck Cancer Updates Preface** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*
Colevas, A.
2015; 29 (6): XIII-XIV
- **Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck** *ONCOLOGIST*
Iberri, D. J., Colevas, A. D.
2015; 20 (12): 1393-1403
- **NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Kurzrock, R., Colevas, A. D., Olszanski, A., Akerley, W., Arteaga, C. L., Carson, W. E., Clark, J. W., DiPersio, J. F., Ettinger, D. S., Morgan, R. J., Schwartzberg, L. S., Venook, A. P., Gocke, et al
2015; 13 (11): 1337-1346
- **Outcomes of Young Patients With Oral Cavity Squamous Cell Carcinoma**
Shah, J. L., Bui, T., Kaplan, M., Colevas, A. D., Le, Q. T., Hara, W.
ELSEVIER SCIENCE INC.2015: S214
- **Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Morgan, R. J., Synold, T. W., Longmate, J. A., Quinn, D. I., Gandara, D., Lenz, H., Ruel, C., Xi, B., Lewis, M. D., Colevas, A. D., Doroshow, J., Newman, E. M.
2015; 76 (5): 897-907
- **Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.** *The oncologist*
Iberri, D. J., Colevas, A. D.
2015
- **Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.** *JAMA dermatology*
Pollom, E. L., Bui, T. T., Chang, A. L., Colevas, A. D., Hara, W. Y.
2015; 151 (9): 998-1001
- **Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.** *JAMA dermatology*
Pollom, E. L., Bui, T. T., Chang, A. L., Colevas, A. D., Hara, W. Y.
2015; 151 (9): 998-1001
- **Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin.** *Head & neck*
Colevas, A. D., Lira, R. R., Colevas, E. A., Lavori, P. W., Chan, C., Shultz, D. B., Chang, K. W.

2015; 37 (8): 1102-1107

- **Head and Neck Cancers, Version 1.2015 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Foote, R. L., Gilbert, J., Gillison, et al
2015; 13 (7): 847-856
- **Head and Neck Cancers, Version 1.2015.** *Journal of the National Comprehensive Cancer Network*
Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Foote, R. L., Gilbert, J., Gillison, et al
2015; 13 (7): 847-856
- **Third party assessment of resection margin status in head and neck cancer.**
Ransohoff, A., Wood, D., Henry, S., Divi, V., Colevas, A.
AMER SOC CLINICAL ONCOLOGY.2015
- **Low pre-operative absolute monocyte count to predict overall survival benefit for oral cavity squamous cell carcinoma**
Bui, T., Shah, J., Kaplan, M., Colevas, A., Quynh-Thu Le, Hara, W.
AMER SOC CLINICAL ONCOLOGY.2015
- **Outcomes of elderly patients treated for oral cavity squamous cell carcinoma**
Shah, J., Kaplan, M., Colevas, A., Quynh-Thu Le, Hara, W.
AMER SOC CLINICAL ONCOLOGY.2015
- **A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma** *CLINICAL CANCER RESEARCH*
Galloway, T. J., Wirth, L. J., Colevas, A. D., Gilbert, J., Bauman, J. E., Saba, N. F., Raben, D., Mehra, R., Ma, A. W., Atoyan, R., Wang, J., Burtness, B., Jimeno, et al
2015; 21 (7): 1566-1573
- **Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.** *Head & neck*
Tang, C., Chan, C., Jiang, W., Murphy, J. D., von Eyben, R., Colevas, A. D., Pinto, H., Lee-Enriquez, N., Kong, C., Le, Q.
2015; 37 (3): 386-392
- **Differentiated Thyroid Cancer: Focus on Emerging Treatments for Radioactive Iodine-Refractory Patients** *ONCOLOGIST*
Gruber, J. J., Colevas, A. D.
2015; 20 (2): 113-126
- **Advances in Nanotechnology and Microfluidics for Human Papillomavirus Diagnostics** *PROCEEDINGS OF THE IEEE*
Tasoglu, S., Tekin, H. C., Inci, F., Knowlton, S., Wang, S., Wang-Johanning, F., Johanning, G., Colevas, D., Demirci, U.
2015; 103 (2): 161-178
- **Phase I Trial of Bortezomib (PS-341; NSC 681239) and "Nonhybrid" (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms** *CLINICAL CANCER RESEARCH*
Holkova, B., Kmiecik, M., Perkins, E. B., Bose, P., Baz, R. C., Roodman, G. D., Stuart, R. K., Ramakrishnan, V., Wan, W., Peer, C. J., Dawson, J., Kang, L., Honeycutt, et al
2014; 20 (22): 5652-5662
- **Head and Neck Cancers, Version 2.2014** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., Haddad, et al
2014; 12 (10): 1454-1487
- **Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.** *Journal of the National Comprehensive Cancer Network*
Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., Haddad, et al
2014; 12 (10): 1454-1487
- **CD271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinoma.** *Oncotarget*

Murillo-Sauca, O., Chung, M. K., Shin, J. H., Karamboulas, C., Kwok, S., Jung, Y. H., Oakley, R., Tysome, J. R., Farnebo, L. O., Kaplan, M. J., Sirjani, D., Divi, V., Holsinger, et al
2014; 5 (16): 6854-6866

- **E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).**
Cmelak, A., Li, S., Marur, S., Zhao, W., Westra, W. H., Chung, C. H., Gillison, M. L., Gilbert, J., Bauman, J. E., Wagner, L. I., Ferris, R. L., Trevarthen, D. R., Colevas, et al
AMER SOC CLINICAL ONCOLOGY.2014
- **Targeting CD137 enhances the efficacy of cetuximab.** *journal of clinical investigation*
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., Troutner, E., Richards, L., Rajapaska, et al
2014; 124 (6): 2668-2682
- **Targeting CD137 enhances the efficacy of cetuximab.** *journal of clinical investigation*
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., Troutner, E., Richards, L., Rajapaska, et al
2014; 124 (6): 2668-2682
- **Review of pathologic diagnosis in head and neck cancer patients: Why do it?**
Zhu, G., Lira, R. R., Colevas, A.
AMER SOC CLINICAL ONCOLOGY.2014
- **E1308: Reduced-dose INERT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).**
Cmelak, A., Li, S., Marur, S., Zhao, W., Westra, W. H., Chung, C. H., Gillison, M. L., Gilbert, J., Bauman, J. E., Wagner, L. I., Ferris, R. L., Trevarthen, D. R., Colevas, et al
AMER SOC CLINICAL ONCOLOGY.2014
- **Population-based evaluation of incidence trends in oropharyngeal cancer focusing on socioeconomic status, sex, and race/ethnicity** *HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK*
Colevas, A. D.
2014; 36 (1): 34-42
- **Phase 1b, Multicenter, Single Blinded, Placebo-Controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects With Locally Advanced Head and Neck Cancer Receiving Induction Chemotherapy** *CANCER*
Limaye, S. A., Haddad, R. I., Cilli, F., Sonis, S. T., Colevas, A. D., Brennan, M. T., Hu, K. S., Murphy, B. A.
2013; 119 (24): 4268-4276
- **Long-Term Outcomes of Surgery Followed by Radiation Therapy for Minor Salivary Gland Carcinomas** *LARYNGOSCOPE*
Zeidan, Y. H., Shultz, D. B., Murphy, J. D., Chan, C., Kaplan, M. J., Colevas, A. D., Kong, C., Chang, D. T., Le, Q.
2013; 123 (11): 2675-2680
- **Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma** *BRITISH JOURNAL OF DERMATOLOGY*
Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., Chang, A. L.
2013; 169 (3): 673-676
- **Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma.** *British journal of dermatology*
Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., Chang, A. L.
2013; 169 (3): 673-676
- **Head and Neck Cancers, Version 2.2013 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Pfister, D. G., Ang, K., Brizel, D. M., Burtneess, B. A., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., Haddad, et al
2013; 11 (8): 917-923
- **Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines.** *Journal of the National Comprehensive Cancer Network*
Pfister, D. G., Ang, K., Brizel, D. M., Burtneess, B. A., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., Haddad, et al

2013; 11 (8): 917-923

- **Stereotactic radiosurgery for retreatment of gross perineural invasion in recurrent cutaneous squamous cell carcinoma of the head and neck.** *American journal of clinical oncology*
Tang, C., Fischbein, N. J., Murphy, J. D., Chu, K. P., Bavan, B., Dieterich, S., Hara, W., Kaplan, M. J., Colevas, A. D., Le, Q.
2013; 36 (3): 293-298
- **E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC)**
Marur, S., Li, S., Cmelak, A., Gillison, M. L., Ferris, R. L., Bauman, J. E., Zhao, W., Westra, W. H., Chung, C. H., Wagner, L. I., Trevarthen, D. R., Jahagirdar, B. N., Colevas, et al
AMER SOC CLINICAL ONCOLOGY.2013
- **Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence.** *Cancer*
Ho, A. S., Tsao, G. J., Chen, F. W., Shen, T., Kaplan, M. J., Colevas, A. D., Fischbein, N. J., Quon, A., Le, Q., Pinto, H. A., Fee, W. E., Sunwoo, J. B., Sirjani, et al
2013; 119 (7): 1349-1356
- **Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence** *CANCER*
Ho, A. S., Tsao, G. J., Chen, F. W., Shen, T., Kaplan, M. J., Colevas, A. D., Fischbein, N. J., Quon, A., Quynh-Thu Le, Q. T., Pinto, H. A., Fee, W. E., Sunwoo, J. B., Sirjani, et al
2013; 119 (7): 1349-1356
- **Biased View of the Role of Site-Specific Therapy in Carcinoma of Unknown Primary.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Percival, M. E., Colevas, A. D.
2013
- **Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
LoRusso, P. M., Piha-Paul, S. A., Mita, M., Colevas, A. D., Malhi, V., Colburn, D., Yin, M., Low, J. A., Graham, R. A.
2013; 71 (1): 193-202
- **Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors** *INVESTIGATIONAL NEW DRUGS*
Kunz, P. L., He, A. R., Colevas, A. D., Pishvaian, M. J., Hwang, J. J., Clemens, P. L., Messina, M., Kaleta, R., Abrahao, F., Sikic, B. I., Marshall, J. L.
2012; 30 (6): 2364-2370
- **Postoperative Radiation Therapy for Minor Salivary Gland Carcinomas of the Head and Neck: Long-term Outcomes**
Zeidan, Y., Murphy, J. D., Chan, C., An, Y., Kaplan, M., Colevas, A., Kong, C., Le, Q.
ELSEVIER SCIENCE INC.2012: S500
- **A Phase 2 Trial of Flavopiridol (Alvocidib) and Cisplatin in Platin-Resistant Ovarian and Primary Peritoneal Carcinoma: MC0261** *GYNECOLOGIC ONCOLOGY*
Bible, K. C., Peethambaram, P. P., Oberg, A. L., Maples, W., Groteluschen, D. L., Boente, M., Burton, J. K., Dahl, L. C., Tibodeau, J. D., Isham, C. R., Maguire, J. L., Shridhar, V., Kukla, et al
2012; 127 (1): 55-62
- **Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Trakul, N., Chang, C. N., Harris, J., Chapman, C., Rao, A., Shen, J., Quinlan-Davidson, S., Filion, E. J., Wakelee, H. A., Colevas, A. D., Whyte, R. I., Dieterich, S., Maxim, et al
2012; 84 (1): 231-237
- **A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours** *BRITISH JOURNAL OF CANCER*
Diaz-Padilla, I., Siu, L. L., San Pedro-Salcedo, M., Razak, A. R., Colevas, A. D., Shepherd, F. A., Leighl, N. B., Neal, J. W., Thibault, A., Liu, L., Lisano, J., Gao, B., Lawson, et al
2012; 107 (4): 604-611

- **Validation that metabolic tumor volume predicts outcome in head-and-neck cancer.** *International journal of radiation oncology, biology, physics*
Tang, C., Murphy, J. D., Khong, B., La, T. H., Kong, C., Fischbein, N. J., Colevas, A. D., Iagaru, A. H., Graves, E. E., Loo, B. W., Le, Q.
2012; 83 (5): 1514-1520
- **Validation that Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Tang, C., Murphy, J. D., Khong, B., La, T. H., Kong, C., Fischbein, N. J., Colevas, A. D., Iagaru, A. H., Graves, E. E., Loo, B. W., Quynh-Thu Le, Q. T.
2012; 83 (5): 1514-1520
- **A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma** *MELANOMA RESEARCH*
Kim, K. B., Prieto, V., Joseph, R. W., Diwan, A. H., Gallick, G. E., Papadopoulos, N. E., Bedikian, A. Y., Camacho, L. H., Hwu, P., Ng, C. S., Wei, W., Johnson, M. M., Wittemer, et al
2012; 22 (4): 294-301
- **Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl(+) hematological malignancies** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Bose, P., Perkins, E. B., Honeycut, C., Wellons, M. D., Stefan, T., Jacobberger, J. W., Kontopodis, E., Beumer, J. H., Egorin, M. J., Imamura, C. K., Figg, W. D., Karp, J. E., Koc, et al
2012; 69 (6): 1657-1667
- **Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M., Lund, P., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W., Clarke, M. F., Carlson, R. W., Sunwoo, J., Tedder, et al
AMER SOC CLINICAL ONCOLOGY.2012
- **Hearing evaluation of head and neck cancer patients (HNCP): Comparison of adverse event (AE) criteria**
Colevas, A., Lira, R. R., Colevas, E. A., Lavori, P. W., Chang, K. W.
AMER SOC CLINICAL ONCOLOGY.2012
- **Phase Ib, multicenter, single-blinded, placebo-controlled, sequential dose-escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer (LAHNC) receiving induction chemotherapy (ICT).** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Limaye, S. A., Sonis, S. T., Cilli, F., Colevas, A. D., Brennan, M., Hu, K., Haddad, R. I., Murphy, B. A.
AMER SOC CLINICAL ONCOLOGY.2012
- **ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP).** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Marur, S., Lee, J., Cmelak, A., Zhao, W., Westra, W. H., Chung, C. H., Gillison, M. L., Gilbert, J., Bauman, J. E., Wagner, L. I., Ferris, R. L., Trevarthen, D. R., Colevas, et al
AMER SOC CLINICAL ONCOLOGY.2012
- **Intensity-Modulated Radiotherapy for Tumors of the Nasal Cavity and Paranasal Sinuses: Clinical Outcomes and Patterns of Failure** *52nd Annual Meeting of the American-Society-for-Therapeutic-Radiation-Oncology (ASTRO)*
Wiegner, E. A., Daly, M. E., Murphy, J. D., Abelson, J., Chapman, C. H., Chung, M., Yu, Y., Colevas, A. D., Kaplan, M. J., Fischbein, N., Quynh-Thu Le, Q. T., Chang, D. T.
ELSEVIER SCIENCE INC.2012: 243-51
- **A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Padda, S. K., Krupitskaya, Y., Chhatwani, L., Fisher, G. A., Colevas, A. D., Pedro-Salcedo, M. S., Decker, R., Latz, J. E., Wakelee, H. A.
2012; 69 (4): 1013-1020
- **Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer** *CANCER INVESTIGATION*
Riess, J. W., Logan, A. C., Krupitskaya, Y., Padda, S., Clement-Duchene, C., Ganjoo, K., Colevas, A. D., San Pedro-Salcedo, M., Kuo, C. J., Wakelee, H. A.
2012; 30 (3): 231-235
- **Quantitation of Human Papillomavirus DNA in Plasma of Oropharyngeal Carcinoma Patients** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*

- Cao, H., Banh, A., Kwok, S., Shi, X., Wu, S., Krakow, T., Khong, B., Bavan, B., Bala, R., Pinsky, B. A., Colevas, D., Pourmand, N., Koong, et al
2012; 82 (3): E351-E358
- **Mucosal Melanoma of the Head and Neck** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Pfister, D. G., Ang, K., Brizel, D. M., Burtness, B., Cmelak, A. J., Dimitrios Colevas, A., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., Haddad, R. I., Haughey, B. H., Hicks, et al
2012; 10 (3): 320-338
 - **Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer** *JOURNAL OF CLINICAL INVESTIGATION*
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W., Clarke, M. F., Carlson, R. W., Stockdale, F. E., Mollick, J. A., Chen, et al
2012; 122 (3): 1066-1075
 - **Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial** *LANCET ONCOLOGY*
Lee, N. Y., Zhang, Q., Pfister, D. G., Kim, J., Garden, A. S., Mechalakos, J., Hu, K., Le, Q. T., Colevas, A. D., Glisson, B. S., Chan, A. T., Ang, K. K.
2012; 13 (2): 172-180
 - **The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck.** *Chemotherapy research and practice*
Russell, J. S., Colevas, A. D.
2012; 2012: 761518-?
 - **Evaluation of patients with disseminated or locoregionally advanced thyroid cancer: a primer for medical oncologists.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Colevas, A. D., Shah, M. H.
2012: 384-88
 - **Transsphenoidal Resection of Sellar Tumors Using High-Field Intraoperative Magnetic Resonance Imaging** *SKULL BASE-AN INTERDISCIPLINARY APPROACH*
Szerlip, N. J., Zhang, Y., Placantonakis, D. G., Goldman, M., Colevas, K. B., Rubin, D. G., Kobylarz, E. J., Karimi, S., Girotra, M., Tabar, V.
2011; 21 (4): 223-232
 - **Head and Neck Cancers** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Pfister, D. G., Ang, K., Brizel, D. M., Burtness, B. A., Cmelak, A. J., Colevas, D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., Haddad, R. I., Haughey, B. H., Hicks, et al
2011; 9 (6): 596-649
 - **A POOLED ANALYSIS OF ADVANCED NONSQUAMOUS NSCLC PATIENTS WITH STABLE TREATED BRAIN METASTASES IN TWO PHASE II TRIALS RECEIVING BEVACIZUMAB AND PEMETREXED AS SECOND-LINE THERAPY**
Gubens, M., Akerley, W., Lynch, T., Langer, C. J., Socinski, M. A., Colevas, A., Clement-Duchene, C., Wakelee, H.
LIPPINCOTT WILLIAMS & WILKINS.2011: S1224-S1225
 - **Controversies in the Locoregional Management of Head and Neck Cancer** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Brizel, D. M., Lydiatt, W., Colevas, A. D.
2011; 9 (6): 653-662
 - **Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.**
Sikic, B. I., Eckhardt, S. G., Gallant, G., Burris, H. A., Camidge, D. R., Colevas, A. D., Jones, S. F., Messersmith, W. A., Wakelee, H. A., Li, H., Kaminker, P. G., Morris, S., Infante, et al
AMER SOC CLINICAL ONCOLOGY.2011
 - **Chemoradiation for nasopharyngeal carcinoma (NPC) with pilot hypoxia imaging with F18 misonidazole PET scanning.**
Colevas, A. D., Quon, A., McMillan, A., Le, Q.
AMER SOC CLINICAL ONCOLOGY.2011
 - **A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors**
Rosen, L., LoRusso, P., Ma, W., Goldman, J., Weise, A., Colevas, A., Adjei, A., Yazji, S., Shen, A., Johnston, S., Gates, M. R., Jones, C., Musib, et al

AMER ASSOC CANCER RESEARCH.2011

- **INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX** *HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK*
Daly, M. E., Le, Q., Jain, A. K., Maxim, P. G., Hsu, A., Loo, B. W., Kaplan, M. J., Fischbein, N. J., Colevas, A. D., Pinto, H., Chang, D. T.
2011; 33 (1): 103-111
- **A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer** *JOURNAL OF THORACIC ONCOLOGY*
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., McMillan, A., Kumar, A., Zhao, G., Padda, S., Zhou, L., San Pedro-Salcedo, M., Colevas, A. D., Wakelee, H. A.
2010; 5 (11): 1821-1825
- **HIGHER INCIDENCE OF HEAD AND NECK CANCERS AMONG VIETNAMESE AMERICAN MEN IN CALIFORNIA** *HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK*
Filion, E. J., McClure, L. A., Huang, D., Seng, K., Kaplan, M. J., Colevas, A. D., Gomez, S. L., Chang, E. T., Le, Q.
2010; 32 (10): 1336-1344
- **MOLECULAR AND CLINICAL RESPONSES IN A PILOT STUDY OF GEFITINIB WITH PACLITAXEL AND RADIATION IN LOCALLY ADVANCED HEAD-AND-NECK CANCER** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Van Waes, C., Allen, C. T., Citrin, D., Gius, D., Colevas, A. D., Harold, N. A., Rudy, S., Nottingham, L., Muir, C., Chen, Z., Singh, A. K., Dancey, J., Morris, et al
2010; 77 (2): 447-454
- **Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors.**
Eckhardt, S. G., Gallant, G., Sikic, B. I., Camidge, D. R., Burris, H. A., Wakelee, H. A., Messersmith, W. A., Jones, S. F., Colevas, A. D., Infante, J. R.
AMER SOC CLINICAL ONCOLOGY.2010
- **A phase I study of an oral formulation of ixabepilone (ixa) in patients with advanced cancer**
He, A. R., Kunz, P. L., Pishvaian, M. J., Colevas, A. D., Hwang, J. J., Clemens, P. L., Messina, M., Kaleta, R., Abrahao, F., Sikic, B. I.
AMER SOC CLINICAL ONCOLOGY.2010
- **Nano-immunoassay profiling of ERK and MEK isoforms in fine-needle aspirates of solid tumors**
Fan, A. C., Dermody, J., Kong, C., Zhang, N., Colevas, A. D., Felsher, D. W.
AMER SOC CLINICAL ONCOLOGY.2010
- **Plasma human papillomavirus (HPV) DNA as a potential tool for tumor detection and monitoring response in HPV-related oropharyngeal carcinoma (OP)**
Cao, H., Kwok, S., Shi, X., Bala, R., Pinsky, B., Colevas, A. D., Pourmand, N., Koong, A., Kong, C., Le, Q.
AMER SOC CLINICAL ONCOLOGY.2010
- **A population-based evaluation of incidence trends in oropharynx cancer (OP) focusing on socioeconomic status (SES), sex, and race/ethnicity**
Colevas, A. D., Clarke, C. A., Lichtensztajn, D., Chang, E. T.
AMER SOC CLINICAL ONCOLOGY.2010
- **Toxicity Monitoring: Why, What, When.?** *ONCOLOGY CLINICAL TRIALS*
Colevas, A.
edited by Kelly, W. K., Halabi, S.
2010: 151-61
- **Intensity Modulated Radiotherapy for Tumors of the Nasal Cavity and Paranasal Sinuses: Clinical Outcomes and Patterns of Failure**
Wiegner, E. A., Daly, M. E., Chapman, C. H., Yu, Y., Colevas, A. D., Kaplan, M. J., Fischbein, N., Le, Q. T., Chang, D. T.
ELSEVIER SCIENCE INC.2010: S463
- **Excellent early local control with tumor volume adapted dosing of stereotactic body radiation therapy for pulmonary tumors**
Chang, C. N., Zhou, L. Y., MacFarlane, G., Tran, P., Rao, A., Chapman, C., Le, Q., Wakelee, H., Colevas, A. D., Whyte, R., Hristov, D., Dieterich, S., Maxim, et al
LIPPINCOTT WILLIAMS & WILKINS.2009: S938-S939

- **Quantification of pre-treatment metabolic tumor growth rate in lung cancer**
Eastham, D., Chapman, C. H., Rao, A. K., Balasubramanian, N., Quon, A., Vasanawala, M. S., Wakelee, H., Le, Q., Colevas, D. A., Maxim, P. A., Graves, E., Loo, B. W.
LIPPINCOTT WILLIAMS & WILKINS.2009: S733–S733
- **LONG-TERM OUTCOMES AND TOXICITY OF CONCURRENT PACLITAXEL AND RADIOTHERAPY FOR LOCALLY ADVANCED HEAD-AND-NECK CANCER** *49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology (ASTRO)*
Citrin, D., Mansueti, J., Likhacheva, A., Sciuto, L., Albert, P. S., Rudy, S. F., Cooley-Zgela, T., Cotrim, A., Solomon, B., Colevas, A. D., Russo, A., Morris, J. C., Herscher, et al
ELSEVIER SCIENCE INC.2009: 1040–46
- **Does Pre-treatment Metabolic Tumor Growth Rate (MTGR) Predict Progression in Lung Cancer?** *51st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO)*
Eastham, D. V., Chapman, C. H., Rao, A. K., Narasimhan, B., Quon, A., Vasanawala, M. S., Wakelee, H., Le, Q., Colevas, A. D., Loo, B. W.
ELSEVIER SCIENCE INC.2009: S446–S446
- **Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms**
Grant, S., Sullivan, D., Roodman, D., Stuart, R. K., Perkins, E., Kolla, S., Ramakrishnan, V., Wright, J., Colevas, A., Tombes, M. B., Roberts, J. D.
AMER SOC HEMATOLOGY.2008: 558
- **A multicentre phase II clinical experience with the novel aza-epothilone ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma** *BRITISH JOURNAL OF HAEMATOLOGY*
O'Connor, O. A., Portlock, C., Moskowitz, C., Straus, D., Hamlin, P., Stubblefield, M., Dumetrescu, O., Colevas, A. D., Grant, B., Zelenetz, A.
2008; 143 (2): 201-209
- **Head and neck cancers.** *Journal of the National Comprehensive Cancer Network*
Forastiere, A. A., Ang, K., Brizel, D., Brockstein, B. E., Burtness, B. A., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Goepfert, H., Hicks, W. L., Kies, M. S., Lydiatt, et al
2008; 6 (7): 646-695
- **Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck** *31st Congress of the European-Society-for-Medical-Oncology*
Tang, P. A., Siu, L. L., Chen, E. X., Hotte, S. J., Chia, S., Schwarz, J. K., Pond, G. R., Johnson, C., Colevas, A. D., Synold, T. W., Vasist, L. S., Winquist, E.
SPRINGER.2008: 257–64
- **Intensity modulated radiotherapy for squamous cell carcinoma of the hypopharynx and larynx: Clinical outcomes and patterns of failure**
Daly, M. E., Le, Q. T., Loo, B. W., Maxim, P. G., Pinto, H. A., Colevas, A. D., Fee, W. E., Kaplan, M. J., Chang, D. T.
ELSEVIER SCIENCE INC.2008: S405–S406
- **High incidence of larynx cancers in Vietnamese population in the bay area**
Huang, D. D., Filion, E. J., Chang, E., Colevas, A. D., Kaplan, M. J., Le, Q.
ELSEVIER SCIENCE INC.2008: S484
- **A phase 2 trial of flavopiridol and cisplatin in platinum-resistant ovarian cancer**
Peethambaram, P. P., Burton, J. K., Oberg, A. L., Gomez-Dahl, L. C., Isham, C. R., Tibodeau, J. D., Chomjak, T. L., Colevas, A., Wright, J. J., Erlichman, C., Bible, K. C.
AMER ASSOC CANCER RESEARCH.2007: 3380S–3381S
- **Patient-reported outcomes and the evolution of adverse event reporting in oncology** *JOURNAL OF CLINICAL ONCOLOGY*
Trotti, A., Colevas, A. D., Setser, A., Basch, E.
2007; 25 (32): 5121-5127
- **Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer** *NEW ENGLAND JOURNAL OF MEDICINE*
Posner, M. R., Hershock, D. M., Blajman, C. R., Mickiewicz, E., Winquist, E., Gorbounova, V., Tjulandin, S., Shin, D. M., Cullen, K., Ervin, T. J., Murphy, B. A., Racz, L. E., Cohen, et al
2007; 357 (17): 1705-1715
- **A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors** *INVESTIGATIONAL NEW DRUGS*
Hensley, M. L., Dizon, D., Derosa, F., Venkatraman, E., Sabbatini, P., Chi, D. S., Dupont, J., Colevas, A. D., Spriggs, D., Aghajanian, C.

2007; 25 (4): 335-341

- **Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: A phase II trial in adults with poor-risk acute myelogenous leukemia** *CLINICAL CANCER RESEARCH*
Karp, J. E., Smith, B. D., Levis, M. J., Gore, S. D., Greer, J., Hattenburg, C., Briel, J., Jones, R. J., Wright, J. J., Colevas, A. D.
2007; 13 (15): 4467-4473
- **Inhibition of poly (ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models** *CLINICAL CANCER RESEARCH*
Albert, J. M., Cao, C., Kim, K. W., Willey, C. D., Geng, L., Xiao, D., Wang, H., Sandler, A., Johnson, D. H., Colevas, A. D., Low, J., Rothenberg, M. L., Lu, et al
2007; 13 (10): 3033-3042
- **Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma** *9th Annual Meeting of the Society-for-Neuro-Oncology*
Nabors, L. B., Mikkelsen, T., Rosenfeld, S. S., Hochberg, F., Akella, N. S., Fisher, J. D., Cloud, G. A., Zhang, Y., Carson, K., Wittemer, S. M., Colevas, A. D., Grossman, S. A.
AMER SOC CLINICAL ONCOLOGY.2007: 1651-57
- **A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma** *CANCER BIOLOGY & THERAPY*
Posadas, E. M., Undevia, S., Manchen, E., Wade, J. L., Colevas, A. D., Karrison, T., Vokes, E. E., Stadler, W. M.
2007; 6 (4): 490-493
- **Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia** *BLOOD*
Byrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., Moran, M., Blum, K. A., Rovin, B., Brooker-McEldowney, M., Broering, S., Schaaf, L. J., Johnson, et al
2007; 109 (2): 399-404
- **Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours** *EUROPEAN JOURNAL OF CANCER*
Messersmith, W. A., Rudek, M. A., Baker, S. D., Zhao, M., Collins, C., Colevas, A. D., Donehower, R. C., Carducci, M. A., Wolff, A. C.
2007; 43 (1): 78-86
- **Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone** *ANNALS OF ONCOLOGY*
Mani, S., McDaid, H. M., Grossman, A., Muggia, F., Goel, S., Griffin, T., Colevas, D., Horwitz, S. B., Egorin, M. J.
2007; 18 (1): 190-195
- **Long term followup of a phase I study of concurrent paclitaxel and radiation for locally advanced squamous cell carcinoma of the head and neck** *49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology (ASTRO)*
Mansueti, J., Likhacheva, A., Albert, P., Scuito, L., Harold, N., Rudy, S., Colevas, D., Morris, J. C., Van Waes, C., Citrin, D.
ELSEVIER SCIENCE INC.2007: S444-S444
- **Adverse event reporting in publications compared with sponsor database for cancer clinical trials** *JOURNAL OF CLINICAL ONCOLOGY*
Scharf, O., Colevas, A. D.
2006; 24 (24): 3933-3938
- **Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck** *JOURNAL OF CLINICAL ONCOLOGY*
Colevas, A. D.
2006; 24 (17): 2644-2652
- **Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: Scientific rationale and study design** *CLINICAL GENITOURINARY CANCER*
Beekman, K. W., Colevas, A. D., Cooney, K., DiPaola, R., Dunn, R. L., Gross, M., Keller, E. T., Pienta, K. J., Ryan, C. J., Smith, D., Hussain, M.
2006; 4 (4): 299-302
- **In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent** *CLINICAL CANCER RESEARCH*
Rudek, M. A., Zhao, M., Smith, N. F., Robey, R. W., He, P., Hallur, G., Khan, S., Hidalgo, M., Jimeno, A., Colevas, A. D., Messersmith, W. A., Wolff, A. C., Baker, et al

2005; 11 (23): 8503-8511

- **Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias** *CLINICAL CANCER RESEARCH*
Karp, J. E., Passaniti, A., Gojo, I., Kaufmann, S., Bible, K., Garimella, T. S., Greer, J., Briel, J., Smith, B. D., Gore, S. D., Tidwell, M. L., Ross, D. D., Wright, et al
2005; 11 (23): 8403-8412
- **Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: A southwest oncology group trial S0111** *40th Annual Meeting of the American-Society-of-Clinical-Oncology*
Hussain, M., Tangen, C. M., Lara, P. N., Vaishampayan, U. N., Petrylak, D. P., Colevas, A. D., Sakr, W. A., Crawford, E. D.
AMER SOC CLINICAL ONCOLOGY.2005: 8724-29
- **Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma** *37th Annual Meeting of the American-Society-of-Clinical-Oncology*
Amrein, P. C., Clark, J. R., Supko, J. G., Fabian, R. L., Wang, C. C., Colevas, A. D., Posner, M. R., Deschler, D. G., Rocco, J. W., Finkelstein, D. M., McIntyre, J. F.
JOHN WILEY & SONS INC.2005: 1418-27
- **Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 213 design** *CLINICAL CANCER RESEARCH*
Gadgeel, S. M., Wozniak, A., Boinpally, R. R., Wiegand, R., Heilbrun, L. K., Jain, V., Parchment, R., Colevas, D., Cohen, M. B., LoRusso, P. M.
2005; 11 (17): 6233-6239
- **Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer** *40th Annual Meeting of the American-Society-of-Clinical-Oncology*
Galsky, M. D., Small, E. J., Oh, W. K., Chen, I., Smith, D. C., Colevas, A. D., Martone, L., Curley, T., Delacruz, A., Scher, H. I., Kelly, W. K.
AMER SOC CLINICAL ONCOLOGY.2005: 1439-46
- **Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent** *ONCOLOGY-NEW YORK*
Colevas, A. D., Scharf, O., Schoenfeldt, M.
2004; 18 (14): 1778-?
- **Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma** *INVESTIGATIONAL NEW DRUGS*
Burdette-Radoux, S., Tozer, R. G., Lohmann, R. C., Quirt, I., Ernst, D. S., Walsh, W., Wainman, N., Colevas, A. D., Eisenhauer, E. A.
2004; 22 (3): 315-322
- **The clinical development of new mitotic inhibitors that stabilize the microtubule** *ANTI-CANCER DRUGS*
Mani, S., Macapinlac, M., Goel, S., Verdier-Pinard, D., Fojo, T., Rothenberg, M., Colevas, D.
2004; 15 (6): 553-558
- **HER2 expression in salivary gland carcinomas: Dependence on histological subtype** *CLINICAL CANCER RESEARCH*
Glisson, B., Colevas, A. D., Haddad, R., Krane, J., El-Naggar, A., Kies, M., Costello, R., Summey, C., Arquette, M., Langer, C., Amrein, P. C., Posner, M.
2004; 10 (3): 944-946
- **Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study** *ORAL ONCOLOGY*
Haddad, R., Colevas, A. D., Krane, J. F., Cooper, D., Glisson, B., Amrein, P. C., Weeks, L., Costello, R., Posner, M.
2003; 39 (7): 724-727
- **CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment** *SEMINARS IN RADIATION ONCOLOGY*
Trotti, A., Colevas, A. D., SETSER, A., Rusch, V., Jaques, D., Budach, V., Langer, C., Murphy, B., Cumberlin, R., Coleman, C. N., Rubin, P.
2003; 13 (3): 176-181
- **Development of investigational radiation modifiers** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Colevas, A. D., Brown, J. M., Hahn, S., Mitchell, J., Camphausen, K., Coleman, C. N.
2003; 95 (9): 646-651
- **Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck - The Dana Farber Cancer Institute experience** *CANCER*
Haddad, R., Colevas, A. D., Tishler, R., Busse, P., Goguen, L., Sullivan, C., Norris, C. M., Lake-Willcutt, B., Case, M. A., Costello, R., Posner, M.

2003; 97 (2): 412-418

- **Organ preservation-induction chemotherapy.** *Cancer treatment and research*
Colevas, A. D.
2003; 114: 213-234
- **Timed sequential therapy of acute leukemia with flavopiridol: In vitro model for a phase I clinical trial** *CLINICAL CANCER RESEARCH*
Karp, J. E., Ross, D. D., Yang, W. D., Tidwell, M. L., Wei, Y. T., Greer, J., Mann, D. L., Nakanishi, T., Wright, J. J., Colevas, A. D.
2003; 9 (1): 307-315
- **A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck** *37th Annual Meeting of the American-Society-of-Clinical-Oncology*
Tishler, R. B., Norris, C. M., Colevas, A. D., Lamb, C. C., Karp, D., Busse, P. M., Nixon, A., Frankenthaler, R., Lake-Willcutt, B., Costello, R., Case, M., Posner, M. R.
JOHN WILEY & SONS INC.2002: 1472-81
- **Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN)** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*
Colevas, A. D., Norris, C. M., Tishler, R. B., Lamb, C. C., Fried, M. P., Goguen, L. A., Gopal, H. V., Costello, R., Read, R., Adak, S., Posner, M. R.
2002; 25 (2): 153-159
- **Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Colevas, A. D., Read, R., Thornhill, J., Adak, S., Tishler, R., Busse, P., Li, Y., Posner, M.
2001; 51 (3): 599-604
- **Clinical trials referral resource: Current clinical trials of epothilone B analog (BMS-247550)** *ONCOLOGY-NEW YORK*
Colevas, A. D., West, P. J., Cheson, B. D.
2001; 15 (9): 1168-?
- **A Phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck** *36th Annual Meeting of the American-Society-of-Clinical-Oncology*
Colevas, A. D., Amrein, P. C., Gomolin, H., Barton, J. J., Read, R. R., Adak, S., Benner, S., Costello, R., Posner, M. R.
JOHN WILEY & SONS INC.2001: 326-31
- **Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck** *JOURNAL OF CLINICAL ONCOLOGY*
Posner, M. R., Glisson, B., Frenette, G., al-Sarraf, M., Colevas, A. D., Norris, C. M., Seroskie, J. D., Shin, D. M., Olivares, R., Garay, C. A.
2001; 19 (4): 1096-1104
- **NCCN Practice Guidelines for head and neck cancers** *ONCOLOGY-NEW YORK*
Forastiere, A. A., Pfister, D. G., Ang, K., Brockstein, B., Colevas, A. D., Ellenhorn, J., Goepfert, H., Hicks, W. L., Hong, W. K., Kies, M. S., Lydiatt, W., McCaffrey, T., Mittal, et al
2000; 14 (11A): 163-194
- **The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck** *SEMINARS IN ONCOLOGY*
Posner, M. R., Colevas, A. D., Tishler, R. B.
2000; 27 (4): 13-24
- **A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck** *ANNALS OF ONCOLOGY*
Colevas, A. D., Adak, S., Amrein, P. C., Barton, J. J., Costello, R., Posner, M. R.
2000; 11 (5): 535-539
- **Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck** *JOURNAL OF CLINICAL ONCOLOGY*
Colevas, A. D., Norris, C. M., Tishler, R. B., Fried, M. P., Gomolin, H. I., Amrein, P., Nixon, A., Lamb, C., Costello, R., Barton, J., Read, R., Adak, S., Posner, et al
1999; 17 (11): 3503-3511
- **Re: "Sialadenosis: a presenting sign in Bulemia" (Head and Neck 20: 758-762, 1998)** *Head & neck*
Colevas, A. D.

1999; 21 (6): 582-?

- **An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies** *33rd Annual Meeting of the American-Society-of-Clinical-Oncology*
Tishler, R. B., Busse, P. M., Norris, C. M., Rossi, R., Poulin, M., Thornhill, L., Costello, R., Peters, E. S., Colevas, A. D., Posner, M. R.
ELSEVIER SCIENCE INC.1999: 1001-8
- **Intramucosal spread of malignant melanoma of the oral cavity** *OTOLARYNGOLOGY-HEAD AND NECK SURGERY*
Bhattacharyya, N., Norris, C. M., Colevas, A. D., Chasse, T. A.
1998; 119 (6): 711-711
- **Docetaxel in head and neck cancer - A review** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*
Colevas, A. D., Posner, M. R.
1998; 21 (5): 482-486
- **Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: A phase I/II trial** *JOURNAL OF CLINICAL ONCOLOGY*
Colevas, A. D., Busse, P. M., Norris, C. M., Fried, M., Tishler, R. B., Poulin, M., Fabian, R. L., Fitzgerald, T. J., Dreyfuss, A., Peters, E. S., Adak, S., Costello, R., Barton, et al
1998; 16 (4): 1331-1339
- **The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck.** *oncologist*
Posner, Johnston, Tishler, ANDERSEN, Fiorentino, Busse, Cavacini, Colevas, Clark, NORRIS
1998; 3 (6): 424-431
- **Future directions in the treatment of squamous cell carcinoma of the head and neck: the role of UFT.** *Oncology (Williston Park, N.Y.)*
Colevas, A. D.
1997; 11 (9): 86-89